drug,ccle_drug_name,ccle_target,gdsc_drug_name,gdsc_synonyms,gdsc_target,gdsc_target_pathway,ctrp_drug_name,ctrp_target,ctrp_target_description,synonyms
(5z)-7-oxozeaenol,,,(5Z)-7-Oxozeaenol,"5Z-7-Oxozeaenol, LL-Z1640-2",TAK1 ,"Other, kinases",,,,5Z-7-Oxozeaenol; LL-Z1640-2; (5Z)-7-Oxozeaenol
16-beta-bromoandrosterone,,,,,,,16-beta-bromoandrosterone,,dehydroepiandrosterone (DHEA) analog,16-beta-bromoandrosterone
"1s,3r-rsl-3",,,,,,,"1S,3R-RSL-3",GPX4,synthetic lethal with HRAS in engineered cells; inhibitor of GPX4,"1S,3R-RSL-3"
3-cl-ahpc,,,,,,,3-Cl-AHPC,NR0B2,binder of nuclear receptor SHP,3-Cl-AHPC
5-fluorouracil,,,5-Fluorouracil,5-FU,Antimetabolite (DNA & RNA),Other,,,,5-FU; 5-Fluorouracil
968,,,,,,,968,GLS,inhibitor of glutaminase,968
a-443654,,,A-443654,KIN001-139,AKT1; AKT2; AKT3,PI3K/MTOR signaling,,,,A-443654; KIN001-139
a-770041,,,A-770041,KIN001-111,LCK; FYN,"Other, kinases",,,,KIN001-111; A-770041
a-804598,,,,,,,A-804598,P2RX7,inhibitor of purinergic receptor P2X,A-804598
aa-cocf3,,,,,,,AA-COCF3,FAAH; PLA2G4A; PLA2G4B; PLA2G4C; PLA2G4D,inhibitor of cytosolic phospholipase A2; inhibitor of fatty acid amide hydrolase,AA-COCF3
abiraterone,,,,,,,abiraterone,CYP17A1,"inhibitor of 17 alpha-hydroxylase and C17,20 lyase",abiraterone
abt-199,,,,,,,ABT-199,BCL2,inhibitor of BCL2,ABT-199
abt-737,,,,,,,ABT-737,BCL2; BCL2L1; BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W",ABT-737
ac55649,,,,,,,AC55649,RARB,agonist of retinoic acid receptor beta,AC55649
aew541,AEW541,IGF1R,,,,,,,,AEW541
afatinib,,,Afatinib,"BIBW2992, Tovok, Gilotrif",ERBB2; EGFR,EGFR signaling,afatinib,EGFR; ERBB2,inhibitor of EGFR and HER2,Gilotrif; Afatinib; Tovok; BIBW2992; afatinib
agk-2,,,,,,,AGK-2,SIRT2,inhibitor of sirtuin 2,AGK-2
aica ribonucleotide,,,AICA Ribonucleotide,"AICAR, N1-(b-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide",AMPK agonist,Metabolism,,,,AICA Ribonucleotide; N1-(b-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide; AICAR
akt inhibitor viii,,,AKT inhibitor VIII,Akti-1/2,AKT1; AKT2; AKT3,PI3K/MTOR signaling,,,,Akti-1/2; AKT inhibitor VIII
alectinib,,,Alectinib,"CH5424802, CH 542802, Alecensa",ALK,RTK signaling,,,,CH5424802; Alectinib; Alecensa; CH 542802
alisertib,,,,,,,alisertib,AURKA; AURKB,inhibitor of aurora kinases A and B,alisertib
alisertib:navitoclax (2:1 mol/mol),,,,,,,alisertib:navitoclax (2:1 mol/mol),AURKA; AURKB; BCL2; BCL2L1; BCL2L2,"inhibitor of aurora kinases A and B;inhibitor of BCL2, BCL-xL, and BCL-W",alisertib:navitoclax (2:1 mol/mol)
alvocidib,,,,,,,alvocidib,CDK1; CDK2; CDK4; CDK6,inhibitor of cyclin-dependent kinases,alvocidib
am-580,,,,,,,AM-580,RARA,agonist of retinoic acid receptor alpha,AM-580
amuvatinib,,,Amuvatinib,"MP470, MP 470, MP-470",KIT; PDGFRA; FLT3,"Other, kinases",,,,MP470; MP-470; MP 470; Amuvatinib
apicidin,,,,,,,apicidin,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",apicidin
ar-42,,,AR-42,"HDAC-42, AR 42, AR42",HDAC1,Chromatin histone acetylation,,,,HDAC-42; AR 42; AR-42; AR42
as601245,,,AS601245,,JNK1; JNK2; JNK2,JNK and p38 signaling,,,,AS601245
as605240,,,AS605240,"KIN001-173, AS-605240",PI3Kgamma,PI3K/MTOR signaling,,,,AS605240; KIN001-173; AS-605240
at-406,,,,,,,AT-406,XIAP,SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs),AT-406
at-7519,,,AT-7519,AT7519,CDK1; CDK2; CDK4; CDK6; CDK9,Cell cycle,,,,AT-7519; AT7519
at13387,,,,,,,AT13387,HSP90AA1,inhibitor of HSP90,AT13387
at7867,,,,,,,AT7867,AKT1; AKT2; AKT3; RPS6KB2,inhibitor of AKT1/2/3 and S6K,AT7867
austocystin d,,,,,,,austocystin D,,natural product; inducer of DNA damage,austocystin D
avagacestat,,,Avagacestat,"BMS-708163, BMS 708163",Amyloid beta20; Amyloid beta40,Other,,,,BMS 708163; BMS-708163; Avagacestat
avicin d,,,,,,,avicin D,,natural product,avicin D
avrainvillamide,,,,,,,avrainvillamide,NPM1,natural product; inhibitor of nucleophosmin,avrainvillamide
axitinib,,,Axitinib,"AG-13736, Inlyta",PDGFR; KIT; VEGFR,RTK signaling,axitinib,FLT1; FLT3; KDR; KIT; PDGFRA; PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta",Inlyta; AG-13736; Axitinib; axitinib
az-3146,,,,,,,AZ-3146,TTK,inhibitor of TTK protein kinase,AZ-3146
az628,,,AZ628,"AZ-628, AZ 628",BRAF,ERK MAPK signaling,,,,AZ-628; AZ628; AZ 628
azacitidine,,,,,,,azacitidine,DNMT1,inhibitor of DNA methyltransferase,azacitidine
azd1480,,,,,,,AZD1480,JAK1; JAK2,inhibitor of Janus kinases 1 and 2,AZD1480
azd4547,,,,,,,AZD4547,FGFR1; FGFR2; FGFR3,inhibitor of fibroblast growth factor receptors,AZD4547
azd6482,,,AZD6482,"AZD 6482, AZD-6482, AK-55409",PI3Kbeta,PI3K/MTOR signaling,AZD6482,PIK3CB; PIK3CD,inhibitor of PI3K catalytic subunits beta and delta,AZD-6482; AZD6482; AK-55409; AZD 6482
azd7545,,,,,,,AZD7545,PDK2,inhibitor of pyruvate dehydrogenase kinase 2,AZD7545
azd7762,,,AZD7762,"AZD-7762, AZD 7762",CHEK1; CHEK2,Cell cycle,AZD7762,CHEK1; CHEK2,inhibitor of checkpoint kinases 1 and 2,AZD 7762; AZD7762; AZD-7762
azd8055,,,AZD8055,AZD-8055,MTORC1; MTORC2,PI3K/MTOR signaling,AZD8055,MTOR,inhibitor of mTOR,AZD-8055; AZD8055
b02,,,,,,,B02,RAD51,inhibitor of RAD51,B02
bafilomycin a1,,,,,,,bafilomycin A1,ATP6V0A1,inhibitor of the vacuolar-type H+-ATPase,bafilomycin A1
barasertib,,,,,,,barasertib,AURKB,inhibitor of aurora kinase B,barasertib
bardoxolone methyl,,,,,,,bardoxolone methyl,,electrophilic inducer of the NFE2L2-KEAP1 pathway,bardoxolone methyl
bax channel blocker,,,,,,,Bax channel blocker,BAX,inhibitor of BAX-mediated mitochondrial cytochrome c release,Bax channel blocker
bay-61-3606,,,BAY-61-3606,"Syk Inhibitor, BAY-613606",SYK,"Other, kinases",,,,Syk Inhibitor; BAY-613606; BAY-61-3606
bcl-lzh-4,,,,,,,BCL-LZH-4,,"inhibitor of BCL2, BCL-xL, and MCL1",BCL-LZH-4
bec,,,,,,,BEC,ARG1; ARG2,inhibitor of arginase I and II,BEC
belinostat,,,Belinostat,"PXD101, PXD-101",HDAC1,Chromatin histone acetylation,belinostat,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Belinostat; PXD101; PXD-101; belinostat
bendamustine,,,,,,,bendamustine,,DNA alkylator,bendamustine
betulinic acid,,,,,,,betulinic acid,,natural product; inhibitor of specificity protein 1 transcription factor in cells,betulinic acid
bexarotene,,,Bexarotene,"LG-100069, Targretin, Targret, Targrexin, Targretyn, Bexarotenum",Retinioic X receptor (RXR) agonist,Other,bexarotene,RXRA; RXRB; RXRG,inhibitor of retinoid X receptors,Targrexin; Bexarotene; Targretin; LG-100069; Bexarotenum; bexarotene; Targretyn; Targret
bi-2536,,,BI-2536,,PLK1; PLK2; PLK3,Cell cycle,BI-2536,PLK1,inhibitor of polo-like kinase 1 (PLK1),BI-2536
bibr-1532,,,,,,,BIBR-1532,TERT,inhibitor of telomerase reverse transcriptase,BIBR-1532
bicalutamide,,,Bicalutamide,"ICI-176334, Casodex, Cosudex, ICI 176334",AR,Hormone-related,,,,Casodex; ICI-176334; ICI 176334; Bicalutamide; Cosudex
birinapant,,,,,,,birinapant,DIABLO; XIAP,SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs),birinapant
bix-01294,,,,,,,BIX-01294,EHMT2,inhibitor of G9a histone methyltransferase,BIX-01294
bix02189,,,BIX02189,BIX 02189,MEK5; ERK5,ERK MAPK signaling,,,,BIX02189; BIX 02189
blebbistatin,,,,,,,blebbistatin,MYH1; MYH2,inhibitor of myosin II ATPases,blebbistatin
bleomycin,,,Bleomycin,,dsDNA break induction,DNA replication,,,,Bleomycin
bleomycin (50 um),,,Bleomycin (50 uM),,dsDNA break induction,DNA replication,,,,Bleomycin (50 uM)
bleomycin a2,,,,,,,bleomycin A2,,inducer of DNA damage,bleomycin A2
bms-195614,,,,,,,BMS-195614,RARA; RARB; RARG,antagonist of retinoic acid receptors,BMS-195614
bms-270394,,,,,,,BMS-270394,RARG,antagonist of retinoic acid receptor gamma,BMS-270394
bms-345541,,,BMS-345541,"BMS345541, IKK Inhibitor 3",IKK1; IKK2,"Other, kinases",BMS-345541,IKBKB,inhibitor of IKK-2,BMS-345541; BMS345541; IKK Inhibitor 3
bms-509744,,,BMS-509744,"KIN001-127, ITK inhibitor",ITK,Other,,,,ITK inhibitor; BMS-509744; KIN001-127
bms-536924,,,BMS-536924,BMS 536924,IGF1R; IR,IGFR signaling,BMS-536924,IGF1R; INSR,inhibitor of insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (INSR),BMS 536924; BMS-536924
bms-754807,,,BMS-754807,"BMS754807, BMS 754807",IGF1R; IR,IGFR signaling,BMS-754807,IGF1R,inhibitor of insulin-like growth factor 1 receptor and insulin receptor,BMS-754807; BMS754807; BMS 754807
bortezomib,,,Bortezomib,"PS-341, LDP-341, Velcade",Proteasome,Protein stability and degradation,bortezomib,PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of 26S proteasome,LDP-341; bortezomib; Velcade; PS-341; Bortezomib
bosutinib,,,Bosutinib,"SKI-606, Bosulif",SRC; ABL; TEC,"Other, kinases",bosutinib,ABL1; SRC,inhibitor of SRC and ABL1,Bosulif; Bosutinib; SKI-606; bosutinib
brd-a02303741,,,,,,,BRD-A02303741,DOT1L,inhibitor of histone methyltransferases,BRD-A02303741
brd-a02303741:carboplatin (1:1 mol/mol),,,,,,,BRD-A02303741:carboplatin (1:1 mol/mol),DOT1L,inhibitor of histone methyltransferases;inducer of DNA damage,BRD-A02303741:carboplatin (1:1 mol/mol)
brd-a02303741:navitoclax (2:1 mol/mol),,,,,,,BRD-A02303741:navitoclax (2:1 mol/mol),DOT1L; BCL2; BCL2L1; BCL2L2,"inhibitor of histone methyltransferases;inhibitor of BCL2, BCL-xL, and BCL-W",BRD-A02303741:navitoclax (2:1 mol/mol)
brd-a05715709,,,,,,,BRD-A05715709,IDH1,putative inhibitor of IDH1 R132H,BRD-A05715709
brd-a71883111,,,,,,,BRD-A71883111,IDH1,putative inhibitor of IDH1 R132H,BRD-A71883111
brd-a86708339,,,,,,,BRD-A86708339,,screening hit,BRD-A86708339
brd-a94377914,,,,,,,BRD-A94377914,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",BRD-A94377914
brd-k01737880,,,,,,,BRD-K01737880,,screening hit,BRD-K01737880
brd-k02251932,,,,,,,BRD-K02251932,,product of diversity oriented synthesis,BRD-K02251932
brd-k02492147,,,,,,,BRD-K02492147,,product of diversity oriented synthesis,BRD-K02492147
brd-k03536150,,,,,,,BRD-K03536150,BAX,activator of BAX,BRD-K03536150
brd-k03911514,,,,,,,BRD-K03911514,,stapled helical peptide,BRD-K03911514
brd-k04800985,,,,,,,BRD-K04800985,,product of diversity oriented synthesis,BRD-K04800985
brd-k07442505,,,,,,,BRD-K07442505,BAX,stapled helical peptide activating BAX,BRD-K07442505
brd-k09344309,,,,,,,BRD-K09344309,,screening hit,BRD-K09344309
brd-k09587429,,,,,,,BRD-K09587429,,product of diversity oriented synthesis,BRD-K09587429
brd-k11533227,,,,,,,BRD-K11533227,HDAC1; HDAC2,inhibitor of HDAC1 and HDAC2,BRD-K11533227
brd-k13185470,,,,,,,BRD-K13185470,MCL1,stapled helical peptide targeting MCL1,BRD-K13185470
brd-k13999467,,,,,,,BRD-K13999467,,product of diversity oriented synthesis,BRD-K13999467
brd-k14844214,,,,,,,BRD-K14844214,,product of diversity oriented synthesis,BRD-K14844214
brd-k16130065,,,,,,,BRD-K16130065,,stapled helical peptide,BRD-K16130065
brd-k16147474,,,,,,,BRD-K16147474,,product of diversity oriented synthesis,BRD-K16147474
brd-k17060750,,,,,,,BRD-K17060750,,product of diversity oriented synthesis,BRD-K17060750
brd-k19103580,,,,,,,BRD-K19103580,,product of diversity oriented synthesis,BRD-K19103580
brd-k20514654,,,,,,,BRD-K20514654,,stapled helical peptide,BRD-K20514654
brd-k24690302,,,,,,,BRD-K24690302,HDAC1,inhibitor of HDAC1,BRD-K24690302
brd-k26531177,,,,,,,BRD-K26531177,,analog of the natural product piperlongumine,BRD-K26531177
brd-k27188169,,,,,,,BRD-K27188169,,stapled helical peptide,BRD-K27188169
brd-k27188169:navitoclax (2:1 mol/mol),,,,,,,BRD-K27188169:navitoclax (2:1 mol/mol),BCL2; BCL2L1; BCL2L2,"stapled helical peptide;inhibitor of BCL2, BCL-xL, and BCL-W",BRD-K27188169:navitoclax (2:1 mol/mol)
brd-k27224038,,,,,,,BRD-K27224038,,product of diversity oriented synthesis,BRD-K27224038
brd-k27986637,,,,,,,BRD-K27986637,,product of diversity oriented synthesis; screening hit,BRD-K27986637
brd-k28456706,,,,,,,BRD-K28456706,HNF4A,inhibitor of hepatocyte nuclear factor 4 alpha,BRD-K28456706
brd-k29086754,,,,,,,BRD-K29086754,,product of diversity oriented synthesis,BRD-K29086754
brd-k29313308,,,,,,,BRD-K29313308,HDAC3,inhibitor of HDAC3,BRD-K29313308
brd-k30019337,,,,,,,BRD-K30019337,,product of diversity oriented synthesis,BRD-K30019337
brd-k30748066,,,,,,,BRD-K30748066,CDK9,inhibitor of CDK9,BRD-K30748066
brd-k33199242,,,,,,,BRD-K33199242,,product of diversity oriented synthesis,BRD-K33199242
brd-k33514849,,,,,,,BRD-K33514849,,screening hit,BRD-K33514849
brd-k34099515,,,,,,,BRD-K34099515,,screening hit,BRD-K34099515
brd-k34222889,,,,,,,BRD-K34222889,,analog of the natural product piperlongumine,BRD-K34222889
brd-k34485477,,,,,,,BRD-K34485477,,product of diversity oriented synthesis,BRD-K34485477
brd-k35604418,,,,,,,BRD-K35604418,MCL1,inhibitor of MCL1,BRD-K35604418
brd-k37390332,,,,,,,BRD-K37390332,,product of diversity oriented synthesis,BRD-K37390332
brd-k41334119,,,,,,,BRD-K41334119,,product of diversity oriented synthesis,BRD-K41334119
brd-k41597374,,,,,,,BRD-K41597374,,product of diversity oriented synthesis,BRD-K41597374
brd-k42260513,,,,,,,BRD-K42260513,EZH2,inhibitor of enhancer of zeste polycomb repressive complex 2 subunit,BRD-K42260513
brd-k44224150,,,,,,,BRD-K44224150,,product of diversity oriented synthesis,BRD-K44224150
brd-k45681478,,,,,,,BRD-K45681478,,product of diversity oriented synthesis; screening hit,BRD-K45681478
brd-k48334597,,,,,,,BRD-K48334597,,product of diversity oriented synthesis,BRD-K48334597
brd-k48477130,,,,,,,BRD-K48477130,,screening hit,BRD-K48477130
brd-k49290616,,,,,,,BRD-K49290616,,product of diversity oriented synthesis,BRD-K49290616
brd-k50799972,,,,,,,BRD-K50799972,,product of diversity oriented synthesis,BRD-K50799972
brd-k51490254,,,,,,,BRD-K51490254,HDAC6; HDAC8,inhibitor of HDAC6 and HDAC8,BRD-K51490254
brd-k51831558,,,,,,,BRD-K51831558,EZH2,inhibitor of enhancer of zeste polycomb repressive complex 2 subunit,BRD-K51831558
brd-k52037352,,,,,,,BRD-K52037352,,product of diversity oriented synthesis,BRD-K52037352
brd-k55116708,,,,,,,BRD-K55116708,,product of diversity oriented synthesis; inhibitor of leukemic stem cells,BRD-K55116708
brd-k55473186,,,,,,,BRD-K55473186,NOTCH1,stapled helical peptide targeting NOTCH1,BRD-K55473186
brd-k58730230,,,,,,,BRD-K58730230,,stapled helical peptide,BRD-K58730230
brd-k61166597,,,,,,,BRD-K61166597,,inhibitor of HDAC1 and HDAC2,BRD-K61166597
brd-k63431240,,,,,,,BRD-K63431240,,product of diversity oriented synthesis; screening hit,BRD-K63431240
brd-k64610608,,,,,,,BRD-K64610608,,product of diversity oriented synthesis; screening hit,BRD-K64610608
brd-k66453893,,,,,,,BRD-K66453893,,product of diversity oriented synthesis,BRD-K66453893
brd-k66532283,,,,,,,BRD-K66532283,HDAC1; HDAC2,inhibitor of HDAC1 and HDAC2,BRD-K66532283
brd-k70511574,,,,,,,BRD-K70511574,PLK1,inhibitor of polo-like kinase 1 (PLK1),BRD-K70511574
brd-k71781559,,,,,,,BRD-K71781559,,screening hit,BRD-K71781559
brd-k71935468,,,,,,,BRD-K71935468,,inducer of ROS,BRD-K71935468
brd-k75293299,,,,,,,BRD-K75293299,,product of diversity oriented synthesis,BRD-K75293299
brd-k78574327,,,,,,,BRD-K78574327,,product of diversity oriented synthesis,BRD-K78574327
brd-k79669418,,,,,,,BRD-K79669418,MDM2; MDM4,inhibitor of MDM4-p53 interaction,BRD-K79669418
brd-k80183349,,,,,,,BRD-K80183349,HDAC1; HDAC2,inhibitor of HDAC1 and HDAC2,BRD-K80183349
brd-k84807411,,,,,,,BRD-K84807411,,product of diversity oriented synthesis,BRD-K84807411
brd-k85133207,,,,,,,BRD-K85133207,HDAC1,inhibitor of HDAC1,BRD-K85133207
brd-k86535717,,,,,,,BRD-K86535717,,product of diversity oriented synthesis,BRD-K86535717
brd-k88742110,,,,,,,BRD-K88742110,HDAC8,inhibitor of HDAC8,BRD-K88742110
brd-k90370028,,,,,,,BRD-K90370028,,screening hit,BRD-K90370028
brd-k92856060,,,,,,,BRD-K92856060,,screening hit,BRD-K92856060
brd-k94991378,,,,,,,BRD-K94991378,,inducer of ROS,BRD-K94991378
brd-k96431673,,,,,,,BRD-K96431673,,product of diversity oriented synthesis,BRD-K96431673
brd-k96970199,,,,,,,BRD-K96970199,,product of diversity oriented synthesis,BRD-K96970199
brd-k97651142,,,,,,,BRD-K97651142,,aphrocallistin derivative,BRD-K97651142
brd-k99006945,,,,,,,BRD-K99006945,,screening hit,BRD-K99006945
brd-k99584050,,,,,,,BRD-K99584050,,stapled helical peptide,BRD-K99584050
brd-m00053801,,,,,,,BRD-M00053801,BCL2,inhibitor of BCL2,BRD-M00053801
brd1812,,,,,,,BRD1812,,screening hit,BRD1812
brd1835,,,,,,,BRD1835,EZH2,product of diversity oriented synthesis; screening hit,BRD1835
brd4132,,,,,,,BRD4132,,screening hit,BRD4132
brd6340,,,,,,,BRD6340,,screening hit,BRD6340
brd8899,,,,,,,BRD8899,STK33,inhibitor of serine/threonine kinasase STK33,BRD8899
brd8958,,,,,,,BRD8958,EP300,inhibitor of E1A binding protein p300,BRD8958
brd9647,,,,,,,BRD9647,,screening hit,BRD9647
brd9876,,,,,,,BRD9876,,screening hit,BRD9876
brd9876:mk-1775 (4:1 mol/mol),,,,,,,BRD9876:MK-1775 (4:1 mol/mol),WEE1,screening hit;inhibitor of WEE1,BRD9876:MK-1775 (4:1 mol/mol)
brefeldin a,,,,,,,brefeldin A,ARF1,modulator of ADP-ribosylation factor 1; inhibitor of protein translocation from ER to Golgi,brefeldin A
brivanib,,,,,,,brivanib,FLT1; KDR,inhibitor of VEGFR 1/2,brivanib
bryostatin 1,,,Bryostatin 1,Bryostatin,PKC,"Other, kinases",,,,Bryostatin; Bryostatin 1
bx-912,,,BX-912,,PDK1 (PDPK1),PI3K/MTOR signaling,,,,BX-912
bx795,,,BX795,BX-795,TBK1; PDK1 (PDPK1); IKK; AURKB; AURKC,Other,,,,BX795; BX-795
byl-719,,,,,,,BYL-719,PIK3CA,inhibitor of PI3K catalytic subunit alpha,BYL-719
c6-ceramide,,,,,,,C6-ceramide,MAPK1; PPP2CA; UGCG,inhibitor of glucosylceramide synthase; activator of MAP kinase (ERK); stimulator of protein phosphatase 2A,C6-ceramide
cabozantinib,,,Cabozantinib,"BMS-907351, XL-184, Cometriq","VEGFR; MET; RET; KIT; FLT1; FLT3; FLT4; TIE2,AXL","Other, kinases",cabozantinib,FLT3; KDR; MET; RET,"inhibitor of c-MET, VEGFR2/3, and RET",BMS-907351; Cabozantinib; XL-184; cabozantinib; Cometriq
camptothecin,,,Camptothecin,"Camptothecine, (+)-Camptothecin",TOP1,DNA replication,,,,(+)-Camptothecin; Camptothecin; Camptothecine
canertinib,,,,,,,canertinib,EGFR; ERBB2,inhibitor of EGFR and HER2,canertinib
carboplatin,,,,,,,carboplatin,,inducer of DNA damage,carboplatin
carboplatin:etoposide (40:17 mol/mol),,,,,,,carboplatin:etoposide (40:17 mol/mol),TOP2A,inducer of DNA damage;inhibitor of topoisomerase II,carboplatin:etoposide (40:17 mol/mol)
carboplatin:unc0638 (2:1 mol/mol),,,,,,,carboplatin:UNC0638 (2:1 mol/mol),EHMT1; EHMT2,inducer of DNA damage;inhibitor of EHMT2 and GLP methyltransferase,carboplatin:UNC0638 (2:1 mol/mol)
cay10576,,,,,,,CAY10576,IKBKE,inhibitor of IKK-epsilon,CAY10576
cay10594,,,,,,,CAY10594,PLD2,inhibitor of phospholipase D2,CAY10594
cay10603,,,CAY10603,,HDAC1; HDAC6,Chromatin histone acetylation,,,,CAY10603
cay10618,,,,,,,CAY10618,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,CAY10618
cbb-1007,,,,,,,CBB-1007,KDM1A,inhibitor of lysine-specific demethylase 1A (LSD1),CBB-1007
cct-018159,,,CCT-018159,"CCT018159, CCT 018159",HSP90,Protein stability and degradation,,,,CCT 018159; CCT018159; CCT-018159
cct007093,,,CCT007093,,PPM1D,Other,,,,CCT007093
cct036477,,,,,,,CCT036477,,inhibitor of WNT signaling by blocking beta-catenin transcription,CCT036477
cd-1530,,,,,,,CD-1530,RARG,agonist of retinoic acid receptor gamma,CD-1530
cd-437,,,,,,,CD-437,RARG,agonist of retinoic acid receptor gamma,CD-437
cediranib,,,,,,,cediranib,FLT1; FLT4; KDR,inhibitor of VEGFRs,cediranib
ceranib-2,,,,,,,ceranib-2,ACER1; ACER2; ACER3; ASAH1; ASAH2; ASAH2B,inhibitor of ceramidase activity,ceranib-2
cerulenin,,,,,,,cerulenin,FASN; HMGCS1,inhibitor of fatty acid synthase; inhibitor of HMG-CoA synthase,cerulenin
cetuximab,,,Cetuximab,"Erbitux, IMC-C225, C225, IMC-225, L01XC06",EGFR,EGFR signaling,,,,C225; L01XC06; Erbitux; IMC-225; Cetuximab; IMC-C225
cgp-082996,,,CGP-082996,"CINK4, KIN001-021",CDK4,Cell cycle,,,,KIN001-021; CGP-082996; CINK4
cgp-60474,,,CGP-60474,"KIN001-019, CGP60474, CGP 60474","CDK1,CDK2,CDK5,CDK7,CDK9; PKC",Cell cycle,,,,CGP 60474; CGP60474; CGP-60474; KIN001-019
ch-55,,,,,,,Ch-55,RARA; RARB; RARG,agonist of retinoid acid receptors,Ch-55
chir-99021,,,CHIR-99021,"CT 99021, CHIR99021, CHIR 99021",GSK3A; GSK3B,WNT signaling,CHIR-99021,GSK3B,inhibitor of GSK3 beta,CHIR99021; CT 99021; CHIR 99021; CHIR-99021
chlorambucil,,,,,,,chlorambucil,,DNA alkylator,chlorambucil
chm-1,,,,,,,CHM-1,,inhibitor of tubulin polymerization,CHM-1
ci-1040,,,CI-1040,"CI 1040, PD-18435, PD-184352, 212631-79-3",MEK1; MEK2,ERK MAPK signaling,,,,PD-18435; CI 1040; PD-184352; CI-1040; 212631-79-3
ci-976,,,,,,,CI-976,ACAT1,inhibitor of acetyl-CoA acetyltransferase I,CI-976
ciclopirox,,,,,,,ciclopirox,RRM1,substituted pyridone antimycotic; inhibitor of the iron-dependent enzyme ribonucleotide reductase,ciclopirox
ciclosporin,,,,,,,ciclosporin,PPID,inhibitor of calcineurin by binding to cyclophilin D,ciclosporin
cid-5951923,,,,,,,CID-5951923,KLF5,modulator of KLF5 expression,CID-5951923
cil41,,,,,,,CIL41,,screening hit,CIL41
cil55,,,,,,,CIL55,,screening hit,CIL55
cil55a,,,,,,,CIL55A,,screening hit,CIL55A
cil56,,,,,,,CIL56,,screening hit,CIL56
cil70,,,,,,,CIL70,,screening hit,CIL70
cimetidine,,,,,,,cimetidine,HRH2,inhibitor of histidine receptor H2,cimetidine
cisplatin,,,Cisplatin,"cis-Diammineplatinum(II) dichloride, Platinol, CIS-DDP",DNA crosslinker,DNA replication,,,,CIS-DDP; Cisplatin; Platinol; cis-Diammineplatinum(II) dichloride
clofarabine,,,,,,,clofarabine,,inducer of DNA damage,clofarabine
cmk,,,CMK,KIN001-128,RSK2,ERK MAPK signaling,,,,CMK; KIN001-128
col-3,,,,,,,COL-3,,analog of tetracycline,COL-3
compound 1541a,,,,,,,Compound 1541A,CASP3; CASP6; CASP7,"activators of executioner procaspases 3, 6, and 7",Compound 1541A
compound 1b,,,,,,,compound 1B,,screening hit,compound 1B
compound 23 citrate,,,,,,,Compound 23 citrate,,analog of natural product cortistatin,Compound 23 citrate
compound 7d-cis,,,,,,,Compound 7d-cis,XPO1,inhibitor of CRM1-mediated nucleocytoplasmic transport,Compound 7d-cis
cp466722,,,CP466722,"CP-466722, CP 466722, 1080622-86-1",ATM,Genome integrity,,,,CP466722; CP 466722; 1080622-86-1; CP-466722
cp724714,,,CP724714,CP-724714,ERBB2,EGFR signaling,,,,CP-724714; CP724714
cr-1-31b,,,,,,,CR-1-31B,EIF4A2; EIF4E; EIF4G1,silvestrol analog; inhibits translation by modulating the eIF4F complex,CR-1-31B
crizotinib,PF2341066,c-MET,Crizotinib,"Xalkori, PF2341066, PF-2341066, PF 2341066",MET; ALK; ROS1,RTK signaling,crizotinib,ALK; MET,inhibitor of c-MET and ALK,Crizotinib; PF-2341066; Xalkori; PF 2341066; PF2341066; crizotinib
crizotinib:plx-4032 (2:1 mol/mol),,,,,,,crizotinib:PLX-4032 (2:1 mol/mol),ALK; MET; BRAF,inhibitor of c-MET and ALK;inhibitor of BRAF,crizotinib:PLX-4032 (2:1 mol/mol)
cucurbitacin i,,,,,,,cucurbitacin I,,natural product; modulator of NFKB1 and STAT3 signaling,cucurbitacin I
cudc-101,,,CUDC-101,CUDC 101,HDAC1-10; EGFR; ERBB2,Other,,,,CUDC-101; CUDC 101
curcumin,,,,,,,curcumin,,natural product; modulator of ROS; modulator of NF-kappa-B signaling,curcumin
cx-5461,,,CX-5461,"CX5461, CX 5461",RNA Polymerase 1,Other,,,,CX5461; CX 5461; CX-5461
cyanoquinoline 11,,,,,,,cyanoquinoline 11,MAP3K8,inhibitor of MAP3K8; inhibitor of phosphorylated EGFR in cells,cyanoquinoline 11
cyclopamine,,,Cyclopamine,,SMO,Other,,,,Cyclopamine
cyclophosphamide,,,,,,,cyclophosphamide,,DNA alkylator,cyclophosphamide
cytarabine,,,Cytarabine,"Ara-Cytidine, Arabinosyl Cytosine, U-19920",Antimetabolite,DNA replication,,,,U-19920; Arabinosyl Cytosine; Ara-Cytidine; Cytarabine
cytarabine hydrochloride,,,,,,,cytarabine hydrochloride,,inducer of DNA damage,cytarabine hydrochloride
cytochalasin b,,,,,,,cytochalasin B,,inhibitor of actin polymerization,cytochalasin B
dabrafenib,,,Dabrafenib,"GSK2118436, Tafinlar",BRAF,ERK MAPK signaling,dabrafenib,BRAF,inhibitor of BRAF,Tafinlar; dabrafenib; GSK2118436; Dabrafenib
dacarbazine,,,,,,,dacarbazine,,DNA alkylator,dacarbazine
dacinostat,,,Dacinostat,"NVP-LAQ824, LAQ824",HDAC1,Chromatin histone acetylation,,,,NVP-LAQ824; Dacinostat; LAQ824
dactolisib,,,Dactolisib,"NVP-BEZ235, BEZ235",PI3K (Class 1); MTORC1; MTORC2,PI3K/MTOR signaling,NVP-BEZ235,MTOR; PIK3CA; PIK3CB; PIK3CD; PIK3CG,inhibitor of PI3K and mTOR kinase activity,Dactolisib; NVP-BEZ235; BEZ235
daporinad,,,Daporinad,"APO866,  FK866, FK866",NAMPT ,Metabolism,daporinad,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,daporinad;  FK866; APO866; FK866; Daporinad
darinaparsin,,,,,,,darinaparsin,,inducer of ROS; inhibitor of microtubule assembly,darinaparsin
dasatinib,,,Dasatinib,"BMS-354825-03, BMS-354825, Sprycel",ABL; SRC; Ephrins; PDGFR; KIT,Other,dasatinib,EPHA2; KIT; LCK; SRC; YES1,"inhibitor of SRC, YES1, EPHA2, c-KIT, and LCK",BMS-354825-03; dasatinib; Sprycel; BMS-354825; Dasatinib
dbeq,,,,,,,DBeQ,VCP,inhibitor of p97 in cells,DBeQ
decitabine,,,,,,,decitabine,DNMT1,inhibitor of DNA methyltransferase,decitabine
decitabine:carboplatin (1:1 mol/mol),,,,,,,decitabine:carboplatin (1:1 mol/mol),DNMT1,inhibitor of DNA methyltransferase;inducer of DNA damage,decitabine:carboplatin (1:1 mol/mol)
decitabine:navitoclax (2:1 mol/mol),,,,,,,decitabine:navitoclax (2:1 mol/mol),DNMT1; BCL2; BCL2L1; BCL2L2,"inhibitor of DNA methyltransferase;inhibitor of BCL2, BCL-xL, and BCL-W",decitabine:navitoclax (2:1 mol/mol)
dexamethasone,,,,,,,dexamethasone,NR3C1,agonist of glucocorticoid receptor,dexamethasone
dinaciclib,,,,,,,dinaciclib,CDK1; CDK2; CDK5; CDK9,inhibitor of cyclin-dependent kinases,dinaciclib
dmog,,,DMOG,Dimethyloxalylglcine,HIF-PH,Metabolism,,,,Dimethyloxalylglcine; DMOG
docetaxel,,,Docetaxel,"RP-56976, Taxotere",Microtubule stabiliser,Mitosis,docetaxel,,inhibitor of microtubule assembly,Taxotere; docetaxel; RP-56976; Docetaxel
docetaxel:tanespimycin (2:1 mol/mol),,,,,,,docetaxel:tanespimycin (2:1 mol/mol),HSP90AA1,inhibitor of microtubule assembly;inhibitor of HSP90,docetaxel:tanespimycin (2:1 mol/mol)
doramapimod,,,Doramapimod,"BIRB-796, BIRB 796",p38; JNK2,JNK and p38 signaling,BIRB-796,MAPK11; MAPK11; MAPK14,inhibitor of p38 MAPK,BIRB 796; BIRB-796; Doramapimod
doxorubicin,,,Doxorubicin,"Doxil, Rubex, Adriamycin, Adriablastin, Doxorubicine",Anthracycline,DNA replication,doxorubicin,TOP2A,inhibitor of topoisomerase II,Doxil; Adriamycin; Doxorubicin; doxorubicin; Adriablastin; Doxorubicine; Rubex
doxorubicin:navitoclax (2:1 mol/mol),,,,,,,doxorubicin:navitoclax (2:1 mol/mol),TOP2A; BCL2; BCL2L1; BCL2L2,"inhibitor of topoisomerase II;inhibitor of BCL2, BCL-xL, and BCL-W",doxorubicin:navitoclax (2:1 mol/mol)
eht-1864,,,EHT-1864,EHT 1864,RAC1; RAC2; RAC3,Cytoskeleton,,,,EHT 1864; EHT-1864
elcpk,,,,,,,ELCPK,,screening hit,ELCPK
elesclomol,,,Elesclomol,STA-4783,HSP90,Protein stability and degradation,,,,STA-4783; Elesclomol
elocalcitol,,,,,,,elocalcitol,VDR,agonist of vitamin D receptor,elocalcitol
embelin,,,Embelin,"Emberine, Embelic acid",XIAP,Apoptosis regulation,,,,Embelin; Emberine; Embelic acid
entinostat,,,Entinostat,MS-275,HDAC1; HDAC3,Chromatin histone acetylation,entinostat,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Entinostat; entinostat; MS-275
enzastaurin,,,Enzastaurin,LY317615,PKCB,"Other, kinases",,,,Enzastaurin; LY317615
epigallocatechin-3-monogallate,,,,,,,epigallocatechin-3-monogallate,,natural product,epigallocatechin-3-monogallate
epothilone b,,,Epothilone B,"Patupilone, EpoB, EPO906, GNF-PF-193",Microtubule stabiliser,Mitosis,,,,Patupilone; EpoB; Epothilone B; EPO906; GNF-PF-193
erastin,,,,,,,erastin,SLC7A11; VDAC1; VDAC2,modulator of voltage-dependent anion channels; inhibitor of solute carrier SLC7A11,erastin
erismodegib,,,,,,,erismodegib,,screening hit,erismodegib
erlotinib,Erlotinib,EGFR,Erlotinib,"Tarceva, RG-1415, CP-358774, OSI-774, Ro-508231, R-1415",EGFR,EGFR signaling,erlotinib,EGFR; ERBB2,inhibitor of EGFR and HER2,Tarceva; CP-358774; RG-1415; erlotinib; Ro-508231; Erlotinib; R-1415; OSI-774
erlotinib:plx-4032 (2:1 mol/mol),,,,,,,erlotinib:PLX-4032 (2:1 mol/mol),EGFR; ERBB2; BRAF,inhibitor of EGFR and HER2;inhibitor of BRAF,erlotinib:PLX-4032 (2:1 mol/mol)
etomoxir,,,,,,,etomoxir,CPT1A,inhibitor of carnitine palmitoyltransferase,etomoxir
etoposide,,,Etoposide,"Etopophos, Vepesid, Eposin, VP-16",TOP2,DNA replication,etoposide,TOP2A,inhibitor of topoisomerase II,Etopophos; Vepesid; etoposide; VP-16; Etoposide; Eposin
etp-46464,,,,,,,ETP-46464,ATM; ATR,inhibitor of serine/threonine-protein kinase ATR,ETP-46464
fedratinib,,,Fedratinib,"TG101348, TG-101348, SAR302503, SAR-302503",JAK2,"Other, kinases",TG-101348,JAK2,inhibitor of Janus kinase 2,TG101348; TG-101348; SAR302503; SAR-302503; Fedratinib
fgin-1-27,,,,,,,FGIN-1-27,TSPO,activator of peripheral benzodiazepine receptor/translocator protein,FGIN-1-27
fh535,,,FH535,,PPARgamma; PPARdelta,WNT signaling,,,,FH535
fingolimod,,,,,,,fingolimod,S1PR1,inhibitor of sphingosine 1-phosphate receptor,fingolimod
fluorouracil,,,,,,,fluorouracil,TYMS,pyrimidine analog; inhibitor of thymidylate synthase,fluorouracil
fluvastatin,,,,,,,fluvastatin,HMGCR,inhibitor of HMG-CoA reductase,fluvastatin
fmk,,,FMK,KIN001-242,RSK,"Other, kinases",,,,FMK; KIN001-242
foretinib,,,Foretinib,"GSK1363089, XL-880, EXEL-2880, GSK089",MET; KDR; TIE2; VEGFR3/FLT4; RON; PDGFR; FGFR1; EGFR,RTK signaling,foretinib,KDR; MET,inhibitor of MET and VEGFR2,foretinib; XL-880; GSK089; EXEL-2880; GSK1363089; Foretinib
fqi-1,,,,,,,FQI-1,,inhibitor of LSF1-mediated transcription,FQI-1
fqi-2,,,,,,,FQI-2,,inhibitor of LSF1-mediated transcription,FQI-2
fr-180204,,,FR-180204,"FR 180204, FR180204, ERK Inhibitor II",ERK1; ERK2,ERK MAPK signaling,,,,FR180204; FR 180204; ERK Inhibitor II; FR-180204
fsc231,,,,,,,FSC231,PICK1,inhibitor of PDZ domain of protein interacting with PRKCA 1 (PICK1),FSC231
fti-277,,,FTI-277,,Farnesyl-transferase (FNTA),Other,,,,FTI-277
fulvestrant,,,,,,,fulvestrant,ESR1; GPER1,antagonist of the estrogen receptor,fulvestrant
fumonisin b1,,,,,,,fumonisin B1,CERS1; CERS2; CERS3; CERS4; CERS5; CERS6,inhibitor of ceramide synthase,fumonisin B1
gant-61,,,,,,,GANT-61,,inhibitor of hedgehog signaling pathway,GANT-61
gdc-0879,,,,,,,GDC-0879,BRAF,inhibitor of BRAF,GDC-0879
gefitinib,,,Gefitinib,"ZD-1839, Iressa",EGFR,EGFR signaling,gefitinib,AKT1; EGFR,inhibitor of EGFR and AKT1,gefitinib; Gefitinib; Iressa; ZD-1839
gemcitabine,,,Gemcitabine,"Gemzar, LY-188011",Pyrimidine antimetabolite,DNA replication,gemcitabine,CMPK1; RRM1; TYMS,"inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase ",Gemcitabine; Gemzar; gemcitabine; LY-188011
genentech cpd 10,,,Genentech Cpd 10,,AURKA; AURKB,Mitosis,,,,Genentech Cpd 10
gmx-1778,,,,,,,GMX-1778,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,GMX-1778
gnf-2,,,GNF-2,KIN001-013,BCR-ABL,ABL signaling,,,,GNF-2; KIN001-013
gossypol,,,,,,,gossypol,BCL2; BCL2L1; LDHA; LDHB; LDHC,inhibitor of lactate dehydrogenase; inhibitor of BCL2 family members,gossypol
gsk-3 inhibitor ix,,,,,,,GSK-3 inhibitor IX,,inhibitor of JAK/STAT signaling,GSK-3 inhibitor IX
gsk-j4,,,,,,,GSK-J4,KDM6A; KDM6B,inhibitor of lysine-specific demethylases,GSK-J4
gsk1059615,,,,,,,GSK1059615,MTOR; PIK3CA; PIK3CB; PIK3CD; PIK3CG,inhibitor of PI3K and mTOR kinase activity,GSK1059615
gsk1070916,,,GSK1070916,GSK-1070916,AURKA; AURKC,Mitosis,,,,GSK1070916; GSK-1070916
gsk1904529a,,,GSK1904529A,"GSK-1904529A, GSK 1904529A",IGF1R; IR,IGFR signaling,,,,GSK 1904529A; GSK1904529A; GSK-1904529A
gsk2636771,,,,,,,GSK2636771,PIK3CB,inhibitor of PI3K catalytic subunit beta,GSK2636771
gsk269962a,,,GSK269962A,GSK 269962A,ROCK1; ROCK2,Cytoskeleton,,,,GSK269962A; GSK 269962A
gsk319347a,,,GSK319347A,"KIN001-135, IKK-3 inhibitor",IKK,Other,,,,GSK319347A; KIN001-135; IKK-3 inhibitor
gsk4112,,,,,,,GSK4112,NR1D1,antagonist of Rev-ErbAalpha,GSK4112
gsk429286a,,,GSK429286A,,ROCK1; ROCK2,Cytoskeleton,,,,GSK429286A
gsk461364,,,,,,,GSK461364,PLK1,inhibitor of polo-like kinase 1 (PLK1),GSK461364
gsk650394,,,GSK650394,"GSK-650394, GSK 650394",SGK2; SGK3,Other,,,,GSK-650394; GSK 650394; GSK650394
gsk690693,,,GSK690693,"GSK 690693, GSK-690693",AKT1; AKT2; AKT3,PI3K/MTOR signaling,,,,GSK 690693; GSK690693; GSK-690693
gw-2580,,,GW-2580,"GX2580, CFMS receptor tyrosine kinase inhibitor",CSF1R,RTK signaling,,,,GW-2580; GX2580; CFMS receptor tyrosine kinase inhibitor
gw-405833,,,,,,,GW-405833,CNR2,partial agonist of cannabinoid receptor 2,GW-405833
gw-843682x,,,,,,,GW-843682X,PLK1; PLK3,inhibitor of PLK1 and PLK3,GW-843682X
gw441756,,,GW441756,GW 441756,NTRK1,RTK signaling,,,,GW 441756; GW441756
gw843682x,,,GW843682X,GW843682X (AN-13),PLK1,Cell cycle,,,,GW843682X; GW843682X (AN-13)
hbx-41108,,,,,,,HBX-41108,USP7,inhibitor of the deubiquitinase activity of USP7,HBX-41108
hc-067047,,,,,,,HC-067047,TRPV4,inhibitor of cation channel TRPV4,HC-067047
hg-5-113-01,,,HG-5-113-01,,LOK; LTK; TRCB; ABL(T315I),Other,,,,HG-5-113-01
hg-5-88-01,,,HG-5-88-01,,EGFR; ADCK4,"Other, kinases",,,,HG-5-88-01
hg6-64-1,,,HG6-64-1,KIN001-206,BRAF,ERK MAPK signaling,,,,HG6-64-1; KIN001-206
hli 373,,,,,,,HLI 373,MDM2,inhibitor of MDM2,HLI 373
hyperforin,,,,,,,hyperforin,TRPC6,agonist of calcium-permeable ion channels,hyperforin
i-bet-762,,,I-BET-762,GSK525762A,BRD2; BRD3; BRD4,Chromatin other,GSK525762A,BRD2; BRD3; BRD4,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,I-BET-762; GSK525762A
i-bet151,,,,,,,I-BET151,BRD2; BRD3; BRD4,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,I-BET151
ibrutinib,,,,,,,ibrutinib,BTK,inhibitor of Bruton's tyrosine kinase,ibrutinib
ic-87114,,,,,,,IC-87114,PIK3CD,inhibitor of PI3K catalytic subunit delta,IC-87114
icl1100013,,,ICL1100013,,N-myristoyltransferase 1/2,Other,,,,ICL1100013
idelalisib,,,Idelalisib,"CAL-101, Zydelig",PI3Kdelta,PI3K/MTOR signaling,CAL-101,PIK3CD,inhibitor of PI3K catalytic subunit delta,Idelalisib; CAL-101; Zydelig
ifosfamide,,,,,,,ifosfamide,,DNA alkylator,ifosfamide
imatinib,,,Imatinib,"Gleevec, STI-571",ABL; KIT; PDGFR,RTK signaling,imatinib,ABL1; BCR; KIT,inhibitor of BCR-ABL1 and c-KIT,Imatinib; STI-571; imatinib; Gleevec
importazole,,,,,,,importazole,KPNB1,inhibitor of importin,importazole
indisulam,,,,,,,indisulam,CA9,inhibitor of carbonic anhydrase isoform IX,indisulam
iox2,,,IOX2,"IOX-2, IOX 2, AK176060",EGLN1,Other,,,,IOX-2; IOX 2; IOX2; AK176060
ipa-3,,,IPA-3,IPA 3,PAK1,Cytoskeleton,,,,IPA 3; IPA-3
ipr-456,,,,,,,IPR-456,PLAUR,inhibitor of the interaction of urokinase receptor with binding partners,IPR-456
irinotecan,Irinotecan,TOP1,,,,,,,,Irinotecan
isoevodiamine,,,,,,,isoevodiamine,,natural product,isoevodiamine
isoliquiritigenin,,,,,,,isoliquiritigenin,,natural product,isoliquiritigenin
isonicotinohydroxamic acid,,,,,,,isonicotinohydroxamic acid,HDAC6,inhibitor of HDAC6,isonicotinohydroxamic acid
isox,,,,,,,ISOX,HDAC6,inhibitor of HDAC6,ISOX
isox:bortezomib (250:1 mol/mol),,,,,,,ISOX:bortezomib (250:1 mol/mol),HDAC6; PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of HDAC6;inhibitor of 26S proteasome,ISOX:bortezomib (250:1 mol/mol)
ispinesib mesylate,,,Ispinesib Mesylate,SB-715992,KSP,Mitosis,,,,SB-715992; Ispinesib Mesylate
istradefylline,,,,,,,istradefylline,ADORA2A,antagonist of the adenosine A2A receptor,istradefylline
itraconazole,,,,,,,itraconazole,,anti-fungal agent; inhibitor of hedgehog signaling pathway,itraconazole
iu1,,,,,,,IU1,USP14,inhibitor of the deubiquitinase activity of USP14,IU1
jnk inhibitor viii,,,JNK Inhibitor VIII,,JNK,JNK and p38 signaling,,,,JNK Inhibitor VIII
jnk-9l,,,JNK-9L,"KIN001-204, JNK inhibitor 9l",JNK2; JNK3,JNK and p38 signaling,,,,JNK inhibitor 9l; KIN001-204; JNK-9L
jq-1:carboplatin (1:1 mol/mol),,,,,,,JQ-1:carboplatin (1:1 mol/mol),BRDT,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inducer of DNA damage,JQ-1:carboplatin (1:1 mol/mol)
jq-1:mk-0752 (1:1 mol/mol),,,,,,,JQ-1:MK-0752 (1:1 mol/mol),BRDT; APH1A; NCSTN; PSEN1; PSENEN,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of gamma-secretase,JQ-1:MK-0752 (1:1 mol/mol)
jq-1:navitoclax (2:1 mol/mol),,,,,,,JQ-1:navitoclax (2:1 mol/mol),BRDT; BCL2; BCL2L1; BCL2L2,"inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of BCL2, BCL-xL, and BCL-W",JQ-1:navitoclax (2:1 mol/mol)
jq-1:unc0638 (2:1 mol/mol),,,,,,,JQ-1:UNC0638 (2:1 mol/mol),BRDT; EHMT1; EHMT2,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of EHMT2 and GLP methyltransferase,JQ-1:UNC0638 (2:1 mol/mol)
jq-1:vorinostat (2:1 mol/mol),,,,,,,JQ-1:vorinostat (2:1 mol/mol),BRDT; HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",JQ-1:vorinostat (2:1 mol/mol)
jq1,,,JQ1,"JQ-1, (+)-JQ-1",BRD2; BRD3; BRD4; BRDT,Chromatin other,JQ-1,BRDT,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,JQ1; JQ-1; (+)-JQ-1
jq12,,,JQ12,,HDAC1; HDAC2,Chromatin histone acetylation,,,,JQ12
jw-480,,,,,,,JW-480,NCEH1,inhibitor of serine hydrolase enzyme NCEH,JW-480
jw-55,,,,,,,JW-55,TNKS,inhibitor of tankyrase,JW-55
jw-7-24-1,,,JW-7-24-1,,LCK,"Other, kinases",,,,JW-7-24-1
jw-7-52-1,,,JW-7-52-1,,MTOR,PI3K/MTOR signaling,,,,JW-7-52-1
jw-74,,,,,,,JW-74,,inhibitor of WNT signaling,JW-74
kh-cb19,,,,,,,KH-CB19,CLK1; CLK4,inhibitor of CDC2-like kinases 1 and 4,KH-CB19
khs101,,,,,,,KHS101,TACC3,"binder of TACC3, a component of the centrosome and mitotic spindle",KHS101
ki8751,,,,,,,Ki8751,KDR; KIT; PDGFRA,"inhibitor of VEGFR2, c-KIT, and PDGFRA",Ki8751
kin001-236,,,KIN001-236,,Angiopoietin-1 receptor,Other,,,,KIN001-236
kin001-244,,,KIN001-244,PDK1 inhibitor 7,PDK1 (PDPK1),"Other, kinases",,,,KIN001-244; PDK1 inhibitor 7
kin001-260,,,KIN001-260,"Bayer IKKb inhibitor, ACHP",IKKB,Other,,,,ACHP; Bayer IKKb inhibitor; KIN001-260
kin001-266,,,KIN001-266,,MAP3K8,"Other, kinases",,,,KIN001-266
kin001-270,,,KIN001-270,"CDK9 inhibitor, CDK9-IN-1",CDK9,Cell cycle,,,,KIN001-270; CDK9-IN-1; CDK9 inhibitor
ko-143,,,,,,,Ko-143,ABCG2,inhibitor of breast cancer resistance protein multidrug transporter (BCRP),Ko-143
kpt185,,,,,,,KPT185,XPO1,inhibitor of exportin 1,KPT185
ku 0060648,,,,,,,KU 0060648,PRKDC,inhibitor of DNA-dependent protein kinase,KU 0060648
ku-0063794,,,,,,,KU-0063794,MTOR,inhibitor of mTOR,KU-0063794
ku-55933,,,KU-55933,KU55933,ATM,Genome integrity,KU-55933,ATM,inhibitor of ataxia telangiectasia mutated (ATM),KU55933; KU-55933
ku-60019,,,,,,,KU-60019,ATM,inhibitor of ataxia telangiectasia mutated (ATM),KU-60019
kw-2449,,,,,,,KW-2449,AURKA; FLT3,inhibitor of FLT3 and AURKA,KW-2449
kx2-391,,,,,,,KX2-391,SRC,peptide mimetic; inhibitor of SRC activity in cells,KX2-391
l-685458,L-685458,GS,,,,,L-685458,APH1A; NCSTN; PSEN1; PSENEN,inhibitor of gamma-secretase,L-685458
lapatinib,Lapatinib,EGFR,Lapatinib,"Tykerb, Tyverb",ERBB2; EGFR,EGFR signaling,lapatinib,EGFR; ERBB2,inhibitor of EGFR and HER2,Tyverb; lapatinib; Lapatinib; Tykerb
lbh-589,,,,,,,LBH-589,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",LBH-589
lbw242,LBW242,XIAP,,,,,,,,LBW242
le-135,,,,,,,LE-135,RARB,antagonist of retinoic acid receptor beta,LE-135
lenalidomide,,,Lenalidomide,"CDC-501, CC-5013, Revlimid",CRBN,Protein stability and degradation,,,,Lenalidomide; CDC-501; Revlimid; CC-5013
lenvatinib,,,,,,,lenvatinib,FLT1; FLT3; KDR; KIT; PDGFRA; PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta",lenvatinib
leptomycin b,,,,,,,leptomycin B,XPO1,inhibitor of exportin 1,leptomycin B
lestaurtinib,,,Lestaurtinib,"CEP-701, SP-924, SPM-924, A-154475, KT-555",FLT3; JAK2; NTRK1; NTRK2; NTRK3,"Other, kinases",,,,A-154475; SPM-924; CEP-701; Lestaurtinib; KT-555; SP-924
lfm-a13,,,LFM-A13,DDE-28,BTK,"Other, kinases",,,,DDE-28; LFM-A13
linifanib,,,Linifanib,"ABT-869, ABT 869",VEGFR1; VEGFR2; VEGFR3; CSF1R; FLT3; KIT,RTK signaling,linifanib,FLT1; FLT3; KDR,inhibitor of VEGFRs,ABT-869; ABT 869; Linifanib; linifanib
linsitinib,,,Linsitinib,"OSI-906, ASP-7487",IGF1R,IGFR signaling,linsitinib,IGF1R; INSR,inhibitor of insulin-like growth factor 1 receptor and insulin receptor,OSI-906; linsitinib; Linsitinib; ASP-7487
lomeguatrib,,,,,,,lomeguatrib,MGMT,inhibitor of methylguanine-DNA methyltransferase,lomeguatrib
lovastatin,,,,,,,lovastatin,HMGCR,inhibitor of HMG-CoA reductase,lovastatin
lrrk2-in-1,,,,,,,LRRK2-IN-1,DCLK1; LRRK2,inhibitor of leucine-rich repeat kinase 2; inhibitor of doublecortin-like kinase,LRRK2-IN-1
luminespib,,,Luminespib,"AUY922, VER-52296,NVP-AUY922,  AUY",HSP90,Protein stability and degradation,,,,"Luminespib;  AUY; AUY922; VER-52296,NVP-AUY922"
ly-2157299,,,,,,,LY-2157299,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptor,LY-2157299
ly-2183240,,,,,,,LY-2183240,FAAH,inhibitor of fatty acid amide hydrolase; inhibitor of anandamide uptake,LY-2183240
manumycin a,,,,,,,manumycin A,FNTA; FNTB,inhibitor of RAS farnesyltransferase,manumycin A
marinopyrrole a,,,,,,,marinopyrrole A,MCL1,natural product; putative inhibitor of MCL1,marinopyrrole A
masitinib,,,Masitinib,"AB1010, Masivet",KIT; PDGFRA; PDGFRB,"Other, kinases",masitinib,KIT; PDGFRA; PDGFRB,"inhibitor of c-KIT, PDGFRA, and PDGFRB",Masivet; Masitinib; masitinib; AB1010
mdivi-1,,,,,,,Mdivi-1,DNM1,inhibitor of dynamin 1; inhibitor of mitrochondrial division inhibitor,Mdivi-1
merck60,,,,,,,Merck60,HDAC1; HDAC2,inhibitor of HDAC1 and HDAC2,Merck60
methotrexate,,,Methotrexate,"Abitrexate, Amethopterin, Rheumatrex, Trexall, Folex",Antimetabolite,DNA replication,methotrexate,DHFR,inhibitor of dihydrofolate reductase,Methotrexate; Folex; Rheumatrex; Trexall; methotrexate; Abitrexate; Amethopterin
methylstat,,,,,,,methylstat,KDM3A; KDM4A; KDM4B; KDM4C; KDM4D,inhibitor of lysine specific demethylases,methylstat
mg-132,,,MG-132,"LLL cpd, MG 132, MG132",Proteasome; CAPN1,Protein stability and degradation,MG-132,PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of the proteosome,MG-132; MG132; MG 132; LLL cpd
mgcd-265,,,,,,,MGCD-265,FLT1; FLT3; KDR; MET,inhibitor of c-MET and VEGFRs,MGCD-265
mi-1,,,,,,,MI-1,MEN1,binder of menin; inhibitor of menin-MLL fusion protein,MI-1
mi-2,,,,,,,MI-2,MEN1,binder of menin; inhibitor of menin-MLL fusion protein,MI-2
midostaurin,,,Midostaurin,"PKC412, benzoylstaurosporine, CGP-41251",PKC; PPK; FLT1; c-FGR; others,Other,,,,CGP-41251; PKC412; Midostaurin; benzoylstaurosporine
mitomycin,,,,,,,mitomycin,,DNA crosslinker,mitomycin
mitomycin-c,,,Mitomycin-C,"Mytozytrex, NSC-26980, MMC, Mitosol, Mitozytrex",DNA crosslinker,DNA replication,,,,MMC; Mytozytrex; Mitomycin-C; Mitosol; NSC-26980; Mitozytrex
mk-0752,,,,,,,MK-0752,APH1A; NCSTN; PSEN1; PSENEN,inhibitor of gamma-secretase,MK-0752
mk-1775,,,,,,,MK-1775,WEE1,inhibitor of WEE1,MK-1775
mk-2206,,,MK-2206,"MK 2206, MK2206",AKT1; AKT2,PI3K/MTOR signaling,MK-2206,AKT1,inhibitor of AKT1,MK 2206; MK-2206; MK2206
ml006,,,,,,,ML006,S1PR3,agonist of sphingosine 1-phosphate receptor 3,ML006
ml029,,,,,,,ML029,,inhibitor of antigen receptor-mediated NFkappaB activity,ML029
ml031,,,,,,,ML031,S1PR2,inhibitor of sphingosine 1-phosphate receptor 2,ML031
ml050,,,,,,,ML050,GPER1,antagonist of GPR30,ML050
ml083,,,,,,,ML083,PKM,activator of muscle pyruvate kinase,ML083
ml162,,,,,,,ML162,,selectively kills engineered cells expressing mutant HRAS,ML162
ml203,,,,,,,ML203,PKM,activator of muscle pyruvate kinase (PKM2),ML203
ml210,,,,,,,ML210,,selectively kills engineered cells expressing mutant HRAS,ML210
ml239,,,,,,,ML239,,ML239; inhibitor of breast cancer stem cell proliferation,ML239
ml258,,,,,,,ML258,BCL2L10,inhibitor of BIM-BCL-B interaction,ML258
ml311,,,,,,,ML311,MCL1,inhibitor of MCL1,ML311
ml312,,,,,,,ML312,SCARB1,"inhibitor of scavenger receptor class B, member 1 (SCARB1)-mediated lipid uptake",ML312
ml320,,,,,,,ML320,GSK3B,inhibitor of GSK3 beta,ML320
ml334 diastereomer,,,,,,,ML334 diastereomer,KEAP1; NFE2L2,inhibitor of KEAP1-NFE2L2 protein-protein interaction,ML334 diastereomer
mln2238,,,,,,,MLN2238,PSMB5,inhibitor of 20S proteasome at the chymotrypsin-like proteolytic (beta-5) site,MLN2238
mln2480,,,,,,,MLN2480,ARAF; BRAF; RAF1,inhibitor of RAF kinases,MLN2480
momelotinib,,,,,,,momelotinib,JAK1; JAK2,inhibitor of Janus kinases 1 and 2,momelotinib
motesanib,,,Motesanib,"AMG-706, AMG 706, AMG706",VEGFR; RET; KIT; PDGFR,RTK signaling,,,,AMG-706; AMG 706; AMG706; Motesanib
mps-1-in-1,,,MPS-1-IN-1,,MPS1,Mitosis,,,,MPS-1-IN-1
mst-312,,,,,,,MST-312,TERT,inhibitor of telomerase reverse transcriptase,MST-312
myricetin,,,,,,,myricetin,,flavonoid antioxidant,myricetin
myriocin,,,,,,,myriocin,SPTLC1; SPTLC2; SPTLC3,inhibitor of serine palmitoyltransferase,myriocin
n9-isopropylolomoucine,,,,,,,N9-isopropylolomoucine,CCNB1; CDK1; CDK5; CDK5R1,inhibitor of CDK1/cyclin B and CDK5/p35 complexes,N9-isopropylolomoucine
nakiterpiosin,,,,,,,nakiterpiosin,,natural product; inhibitor of microtubule assembly,nakiterpiosin
narciclasine,,,,,,,narciclasine,RHOA,activates cellular activity of RhoA; modulator of Rho/Rho kinase/LIM kinase/cofilin signaling,narciclasine
navitoclax,,,Navitoclax,"ABT-263, ABT263, ABT 263",BCL2; BCL-XL; BCL-W,Apoptosis regulation,navitoclax,BCL2; BCL2L1; BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W",ABT263; ABT-263; ABT 263; navitoclax; Navitoclax
navitoclax:birinapant (1:1 mol/mol),,,,,,,navitoclax:birinapant (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; DIABLO; XIAP,"inhibitor of BCL2, BCL-xL, and BCL-W;SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs)",navitoclax:birinapant (1:1 mol/mol)
navitoclax:gemcitabine (1:1 mol/mol),,,,,,,navitoclax:gemcitabine (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; CMPK1; RRM1; TYMS,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase ",navitoclax:gemcitabine (1:1 mol/mol)
navitoclax:mst-312 (1:1 mol/mol),,,,,,,navitoclax:MST-312 (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; TERT,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of telomerase reverse transcriptase",navitoclax:MST-312 (1:1 mol/mol)
navitoclax:piperlongumine (1:1 mol/mol),,,,,,,navitoclax:piperlongumine (1:1 mol/mol),BCL2; BCL2L1; BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W;natural product; modulator of ROS levels",navitoclax:piperlongumine (1:1 mol/mol)
navitoclax:pluripotin (1:1 mol/mol),,,,,,,navitoclax:pluripotin (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; MAPK1; RASAL1,"inhibitor of BCL2, BCL-xL, and BCL-W;promoter of embryonic stem cell self-renewal; inhibitor of Ras-GAP and ERK",navitoclax:pluripotin (1:1 mol/mol)
navitoclax:plx-4032 (1:1 mol/mol),,,,,,,navitoclax:PLX-4032 (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; BRAF,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of BRAF",navitoclax:PLX-4032 (1:1 mol/mol)
navitoclax:sorafenib (1:1 mol/mol),,,,,,,navitoclax:sorafenib (1:1 mol/mol),BCL2; BCL2L1; BCL2L2; BRAF; FLT3; KDR; RAF1,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of BRAF, CRAF, and VEGFR2",navitoclax:sorafenib (1:1 mol/mol)
necrostatin-1,,,,,,,necrostatin-1,RIPK1,inhibitor of receptor-interacting protein kinase 1; inhibitor of the necroptosis cell death pathway,necrostatin-1
necrostatin-7,,,,,,,necrostatin-7,,inhibitor of necroptosis,necrostatin-7
necrosulfonamide,,,,,,,necrosulfonamide,,inhibitor of downstream signaling of RIP3 associated with MLKL,necrosulfonamide
nelarabine,,,,,,,nelarabine,POLA1,deoxyguanosine analog; inhibitor of DNA synthesis,nelarabine
neopeltolide,,,,,,,neopeltolide,,inhibitor of cellular respiration,neopeltolide
neratinib,,,,,,,neratinib,EGFR; ERBB2,inhibitor of EGFR and HER2,neratinib
neuronal differentiation inducer iii,,,,,,,neuronal differentiation inducer III,,induction of rat HCN cell differentiation as judged by induction of neuronal reporter neuroD activity,neuronal differentiation inducer III
ng-25,,,NG-25,NG25,TAK1; MAP4K2,"Other, kinases",,,,NG25; NG-25
niclosamide,,,,,,,niclosamide,STAT3,inhibitor of STAT3 signaling,niclosamide
nilotinib,Nilotinib,ABL,Nilotinib,"Tasigna, AMN 107",ABL,ABL signaling,nilotinib,ABL1; BCR; KIT,"inhibitor of ABL1, BCR, and c-KIT",AMN 107; Tasigna; Nilotinib; nilotinib
nintedanib,,,,,,,nintedanib,FGFR1; FGFR2; FGFR3; FLT1; FLT3; KDR; PDGFRA; PDGFRB,"inhibitor of c-KIT, VEGFRs, PDGFRs, and FGFRs",nintedanib
npc-26,,,,,,,NPC-26,,"induces cell death through a non-apoptotic, mitochondrial-dependent mechanism",NPC-26
npk76-ii-72-1,,,NPK76-II-72-1,,PLK3,Cell cycle,,,,NPK76-II-72-1
nsc 74859,,,,,,,NSC 74859,STAT3,inhibitor of STAT3,NSC 74859
nsc-207895,,,NSC-207895,"XI-006, NSC207895",MDM4,p53 pathway,,,,NSC207895; NSC-207895; XI-006
nsc-87877,,,NSC-87877,NSC 87877,SHP-1 (PTPN6); SHP-2 (PTPN11),Other,,,,NSC-87877; NSC 87877
nsc19630,,,,,,,NSC19630,WRN,inhibitor of Werner syndrome helicase activity,NSC19630
nsc23766,,,,,,,NSC23766,RAC1; TIAM1; TRIO,inhibitor of RAC1-GEF interaction; prevents Rac1 activation by Rac-specific guanine nucleotide exchange factors (GEFs) TrioN and Tiam1,NSC23766
nsc30930,,,,,,,NSC30930,SRD5A2,inhibitor of steroid 5-alpha reductase,NSC30930
nsc48300,,,,,,,NSC48300,TASP1,inhibitor of threonine endopeptidase taspase 1,NSC48300
nsc632839,,,,,,,NSC632839,USP13; USP5,inhibitor of ubiquitin isopeptidase,NSC632839
nsc95397,,,,,,,NSC95397,CDC25A; CDC25B; CDC25C,inhibitor of cell division cycle 25 phosphatase (CDC25),NSC95397
nu7441,,,NU7441,"KU-57788, NU-7432, NU-7741",DNAPK,Genome integrity,,,,KU-57788; NU7441; NU-7432; NU-7741
nutlin-3,Nutlin-3,MDM2,,,,,nutlin-3,MDM2,inhibitor of p53-MDM2 interaction,Nutlin-3; nutlin-3
nutlin-3a (-),,,Nutlin-3a (-),,MDM2,p53 pathway,,,,Nutlin-3a (-)
nvp-231,,,,,,,NVP-231,CERK,inhibitor of ceramide kinase,NVP-231
nvp-adw742,,,,,,,NVP-ADW742,IGF1R,inhibitor of insulin-like growth factor 1 receptor,NVP-ADW742
nvp-bhg712,,,NVP-BHG712,BHG712,EPHB4,Other,,,,BHG712; NVP-BHG712
nvp-bsk805,,,,,,,NVP-BSK805,JAK2,inhibitor of Janus kinase 2,NVP-BSK805
o-6-benzylguanine,,,,,,,O-6-benzylguanine,MGMT,inhibitor of O(6)-alkylguanine DNA alkyltransferases,O-6-benzylguanine
obatoclax,,,Obatoclax Mesylate,"GX15-070MS, Obatoclax, GX15-070",BCL2; BCL-XL; BCL-W; MCL1,Apoptosis regulation,obatoclax,BCL2; BCL2L1; MCL1,"inhibitor of MCL1, BCL2, and BCL-xL",GX15-070; obatoclax; Obatoclax Mesylate; Obatoclax; GX15-070MS
olaparib,,,Olaparib,"AZD2281, KU0059436,  Lynparza",PARP1; PARP2,Genome integrity,olaparib,PARP1; PARP2,inhibitor of poly (ADP-ribose) polymerase 1 and 2, Lynparza; AZD2281; Olaparib; olaparib; KU0059436
oligomycin a,,,,,,,oligomycin A,ATP5L2,inhibitor of mitochondrial ATP synthase,oligomycin A
omacetaxine mepesuccinate,,,,,,,omacetaxine mepesuccinate,,inhibitor of protein translation by preventing protein elongation,omacetaxine mepesuccinate
omipalisib,,,Omipalisib,"GSK2126458, GSK-2126458, EX-8678, GSK458",PI3K (class 1); MTORC1; MTORC2,PI3K/MTOR signaling,,,,Omipalisib; GSK2126458; GSK458; EX-8678; GSK-2126458
osi-027,,,OSI-027,A-1065-5,MTORC1; MTORC2,PI3K/MTOR signaling,OSI-027,MTOR,inhibitor of mTORC1 and mTORC2,A-1065-5; OSI-027
osi-930,,,OSI-930,OSI 930 OSI930,KIT,RTK signaling,OSI-930,KDR; KIT,inhibitor of c-KIT and VEGFR2,OSI 930 OSI930; OSI-930
osu-03012,,,OSU-03012,"AR-12, OSU 03012, OSU03012, PDK1 inhibitor AR-12",PDK1 (PDPK1),"Other, kinases",,,,OSU 03012; PDK1 inhibitor AR-12; AR-12; OSU03012; OSU-03012
ouabain,,,,,,,ouabain,ATP1A1; ATP1A2; ATP1A3; ATP1A4; ATP1B1; ATP1B2; ATP1B3; ATP1B4,cardiac glycoside; inhibitor of the Na+/K+-ATPase,ouabain
oxaliplatin,,,,,,,oxaliplatin,,DNA alkylator; organoplatinum reagent,oxaliplatin
pac-1,,,PAC-1,GTPL5238,Procaspase-3; Procaspase-7,Apoptosis regulation,PAC-1,CASP3,activator of procaspase-3,PAC-1; GTPL5238
paclitaxel,Paclitaxel,TUBB1,Paclitaxel,"BMS-181339-01, Taxol, Onxol, Paxene, Praxel, Abraxane",Microtubule stabiliser,Mitosis,paclitaxel,,inhibitor of microtubule assembly,paclitaxel; Paxene; Abraxane; Paclitaxel; Onxol; BMS-181339-01; Taxol; Praxel
palbociclib,PD-0332991,CDK4,Palbociclib,"PD0332991, PD-0332991, PF-00080665-73",CDK4; CDK6,Cell cycle,,,,PF-00080665-73; Palbociclib; PD-0332991; PD0332991
palmostatin b,,,,,,,palmostatin B,LYPLA1,inhibitor of acyl-protein thioesterase 1,palmostatin B
pandacostat,,,,,,,pandacostat,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",pandacostat
panobinostat,Panobinostat,HDAC,,,,,,,,Panobinostat
parbendazole,,,,,,,parbendazole,,inhibitor of microtubule assembly,parbendazole
parthenolide,,,Parthenolide,,HDAC1 ,Chromatin histone acetylation,parthenolide,,natural product; modulator of ROS; modulator of NF-kappa-B signaling,Parthenolide; parthenolide
pazopanib,,,Pazopanib,Votrient,CSF1R; KIT;  PDGFRA; PDGFRB,RTK signaling,pazopanib,FLT1; FLT3; KDR; KIT; PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFRB",Votrient; pazopanib; Pazopanib
pd 153035,,,,,,,PD 153035,EGFR,inhibitor of EGFR,PD 153035
pd0325901,PD-0325901,MEK,PD0325901,"PD-0325901, PD 0325901",MEK1; MEK2,ERK MAPK signaling,,,,PD-0325901; PD0325901; PD 0325901
pd173074,,,PD173074,"PD-173074, PD 173074",FGFR1; FGFR3,RTK signaling,,,,PD173074; PD 173074; PD-173074
pd318088,,,,,,,PD318088,MAP2K1; MAP2K2,inhibitor of MEK1 and MEK2,PD318088
pdmp,,,,,,,PDMP,UGCG,inhibitor of ceramide glucosyltransferase,PDMP
pelitinib,,,Pelitinib,"EKB-569, EKB 569",EGFR,EGFR signaling,,,,EKB-569; EKB 569; Pelitinib
pevonedistat,,,Pevonedistat,"MLN4924, MLN 4924, MLN-4924",NAE,Other,pevonedistat,NAE1,inhibitor of Nedd-8 activating enzyme,MLN-4924; MLN4924; pevonedistat; MLN 4924; Pevonedistat
pf-184,,,,,,,PF-184,IKBKB,inhibitor of IKK-2,PF-184
pf-3758309,,,,,,,PF-3758309,PAK4,inhibitor of serine/threonine p21-activating kinase 4,PF-3758309
pf-4708671,,,PF-4708671,"PF 4708671, PF4708671",S6K1,PI3K/MTOR signaling,,,,PF 4708671; PF-4708671; PF4708671
pf-4800567 hydrochloride,,,,,,,PF-4800567 hydrochloride,CSNK1D; CSNK1E,inhibitor of casein kinase isoforms delta and epsilon,PF-4800567 hydrochloride
pf-543,,,,,,,PF-543,SPHK1,inhibitor of sphingosine kinase-1,PF-543
pf-562271,,,PF-562271,PF-00562271,FAK; FAK2,Cytoskeleton,,,,PF-00562271; PF-562271
pf-573228,,,,,,,PF-573228,PTK2,inhibitor of focal adhesion kinase,PF-573228
pf-750,,,,,,,PF-750,FAAH,inhibitor of fatty acid amide hydrolase,PF-750
pfi-1,,,PFI-1,,BRD4,Chromatin other,,,,PFI-1
pfi-3,,,PFI-3,BDF00016096,SMARCA2; SMARCA4; PB1,Other,,,,PFI-3; BDF00016096
pha-665752,PHA-665752,c-MET,PHA-665752,"PHA665752, PHA 665752",MET,RTK signaling,,,,PHA665752; PHA 665752; PHA-665752
pha-793887,,,PHA-793887,"PHA793887, PHA 793887",CDK2; CDK7; CDK5,Cell cycle,PHA-793887,CDK1; CDK2; CDK4; CDK5; CDK7; CDK9,inhibitor of cyclin-dependent kinases,PHA-793887; PHA 793887; PHA793887
phenformin,,,Phenformin,DBI,Biguanide agent,Other,,,,DBI; Phenformin
phloretin,,,,,,,phloretin,SLC5A1,natural product; inhibitor of glucose uptake,phloretin
pi-103,,,PI-103,"PI-103, PI103, PI 103",PI3Kalpha; DAPK3; CLK4; PIM3; HIPK2,PI3K/MTOR signaling,PI-103,MTOR; PIK3CA; PIK3CB; PIK3CD; PIK3CG; PRKDC,"inhibitor of DNA-PK, PI3K p110 delta, mTORC1, and catalytic subunits of PI3K",PI-103; PI 103; PI103
pictilisib,,,Pictilisib,"GDC-0941, GDC0941, RG-7621",PI3K (class 1),PI3K/MTOR signaling,GDC-0941,PIK3CA; PIK3CB; PIK3CD; PIK3CG,inhibitor of PI3K kinase activity,GDC-0941; Pictilisib; GDC0941; RG-7621
pifithrin-alpha,,,,,,,pifithrin-alpha,,inhibitor of p53-dependent signaling,pifithrin-alpha
pifithrin-mu,,,,,,,pifithrin-mu,HSPA1A; HSPA1B; HSPA1L; TP53,inhibitor of p53 binding to mitochondria; inhibitor of HSP70,pifithrin-mu
pik-93,,,PIK-93,"PIK 93, PIK93",PI3Kgamma,PI3K/MTOR signaling,PIK-93,PIK3CG,inhibitor of PI3K catalytic subunit gamma,PIK93; PIK-93; PIK 93
piperlongumine,,,Piperlongumine,Piplartine,Induces reactive oxygen species,Other,piperlongumine,,natural product; modulator of ROS levels,piperlongumine; Piplartine; Piperlongumine
piperlongumine:mst-312 (1:1 mol/mol),,,,,,,piperlongumine:MST-312 (1:1 mol/mol),TERT,natural product; modulator of ROS levels;inhibitor of telomerase reverse transcriptase,piperlongumine:MST-312 (1:1 mol/mol)
pitstop2,,,,,,,pitstop2,CLTA; CLTB; CLTC; CLTCL1,inhibitor of clathrin and clathrin-independent endocytosis,pitstop2
pl-di,,,,,,,PL-DI,,dimer of piperlongumine; inducer of ROS,PL-DI
platin,,,,,,,Platin,,DNA alkylator; organoplatinum reagent,Platin
pluripotin,,,,,,,pluripotin,MAPK1; RASAL1,promoter of embryonic stem cell self-renewal; inhibitor of Ras-GAP and ERK,pluripotin
plx-4032,,,,,,,PLX-4032,BRAF,inhibitor of BRAF,PLX-4032
plx4720,PLX4720,RAF,PLX-4720,"PLX4720, PLX 4720",BRAF,ERK MAPK signaling,PLX-4720,BRAF,inhibitor of BRAF,PLX-4720; PLX4720; PLX 4720
ponatinib,,,Ponatinib,"AP24534, AP-24534, KIN001-192, Iclusig",ABL; PDGFRA; VEGFR2; FGFR1; SRC; TIE2; FLT3,RTK signaling,,,,Ponatinib; AP-24534; Iclusig; KIN001-192; AP24534
prima-1,,,,,,,PRIMA-1,TP53,re-activator of the pro-apoptotic activity of mutant p53,PRIMA-1
prima-1-met,,,,,,,PRIMA-1-Met,TP53,re-activator of the pro-apoptotic activity of mutant p53,PRIMA-1-Met
prl-3 inhibitor i,,,,,,,PRL-3 inhibitor I,PTP4A3,inhibitor of phosphatase of regenerating liver-3 (PRL3),PRL-3 inhibitor I
procarbazine,,,,,,,procarbazine,,inducer of DNA damage,procarbazine
prochlorperazine,,,,,,,prochlorperazine,DRD2,inhibitor of dopamine receptor D2,prochlorperazine
purmorphamine,,,,,,,purmorphamine,SMO,activator of smoothened receptor,purmorphamine
px-12,,,,,,,PX-12,TXN,inhibitor of thioredoxin-1,PX-12
pyr-41,,,,,,,PYR-41,UBA1,inhibitor of ubiquitin-activating enzyme in cells,PYR-41
pyrazolanthrone,,,,,,,pyrazolanthrone,MAPK10; MAPK8; MAPK9,inhibitor of Jun N-terminal kinase (JNK) 1/2/3,pyrazolanthrone
pyrimethamine,,,Pyrimethamine,"Daraprim, Chloridine",Dihydrofolate reductase (DHFR),Other,,,,Daraprim; Pyrimethamine; Chloridine
ql-viii-58,,,QL-VIII-58,,MTOR; ATR,Other,,,,QL-VIII-58
ql-x-138,,,QL-X-138,,BTK,"Other, kinases",,,,QL-X-138
ql-xi-92,,,QL-XI-92,,DDR1,Other,,,,QL-XI-92
ql-xii-47,,,QL-XII-47,,BTK; BMX,"Other, kinases",,,,QL-XII-47
ql-xii-61,,,QL-XII-61,,BMX; BTK,"Other, kinases",,,,QL-XII-61
qs-11,,,,,,,QS-11,ARFGAP1,inhibitor of GTPase activating protein of ARF 1 (ARFGAP1),QS-11
qs11,,,QS11,944328-88-5,ARFGAP1,Other,,,,944328-88-5; QS11
quizartinib,,,Quizartinib,"AC220, AC 220, AC-220, Asp-2689",FLT3,RTK signaling,quizartinib,FLT3,inhibtor of VEGFR3,AC220; AC 220; Asp-2689; Quizartinib; AC-220; quizartinib
qw-bi-011,,,,,,,QW-BI-011,EHMT2,inhibitor of G9a histone methyltransferase,QW-BI-011
r428,,,,,,,R428,AXL,inhibitor of the tyrosine-protein kinase receptor UFO,R428
raf265,RAF265,RAF,,,,,RAF265,BRAF; KDR,ihibitor of VEGFR2 and BRAF,RAF265
refametinib,,,Refametinib,"RDEA119, BAY-86-9766, BAY 869766",MEK1; MEK2,ERK MAPK signaling,,,,Refametinib; RDEA119; BAY-86-9766; BAY 869766
regorafenib,,,,,,,regorafenib,BRAF; KDR; KIT; RET,"inhibitor of BRAF, RET, KIT, and VEGFR2",regorafenib
repligen 136,,,,,,,Repligen 136,HDAC3,inhibitor of HDAC3,Repligen 136
rg-108,,,,,,,RG-108,DNMT1,inhibitor of DNA methyltransferase,RG-108
rigosertib,,,,,,,rigosertib,PIK3CA; PIK3CB; PLK1,inhibitor of polo-like kinase 1; inhibitor of PI3K catalytic subunits alpha and beta,rigosertib
rita,,,,,,,RITA,MDM2; TP53,inhibitor of p53-MDM2 interaction,RITA
ro-3306,,,RO-3306,,CDK1,Cell cycle,,,,RO-3306
ro4929097,,,,,,,RO4929097,APH1A; NCSTN; PSEN1; PSENEN,inhibitor of gamma-secretase,RO4929097
rtrail,,,rTRAIL,,TRAIL receptor agonist,Apoptosis regulation,,,,rTRAIL
rucaparib,,,Rucaparib,"PF-01367338, AG-014699, AG-14447, AG-14699",PARP1; PARP2,Genome integrity,,,,AG-14699; PF-01367338; AG-14447; Rucaparib; AG-014699
ruxolitinib,,,Ruxolitinib,"INCB-18424, Ruxolitinib Phosphate, Jakafi",JAK1; JAK2,"Other, kinases",ruxolitinib,JAK1; JAK2,inhibitor of Janus kinases 1 and 2,Jakafi; Ruxolitinib; INCB-18424; Ruxolitinib Phosphate; ruxolitinib
s-trityl-l-cysteine,,,S-Trityl-L-cysteine,"NSC 83265, Tritylcysteine",KIF11,Mitosis,,,,NSC 83265; S-Trityl-L-cysteine; Tritylcysteine
salermide,,,,,,,salermide,SIRT1; SIRT2,inhibitor of sirtuin 1 and sirtuin 2,salermide
salermide:plx-4032 (12:1 mol/mol),,,,,,,salermide:PLX-4032 (12:1 mol/mol),SIRT1; SIRT2; BRAF,inhibitor of sirtuin 1 and sirtuin 2;inhibitor of BRAF,salermide:PLX-4032 (12:1 mol/mol)
salubrinal,,,Salubrinal,EIF-2alpha Inhibitor,EIF2A,Other,,,,EIF-2alpha Inhibitor; Salubrinal
saracatinib,AZD0530,ABL,Saracatinib,"AZD0530, AZD-0530, AZ-10353926",ABL; SRC,RTK signaling,saracatinib,ABL1; SRC,inhibitor of SRC and ABL1,AZD0530; AZD-0530; AZ-10353926; saracatinib; Saracatinib
sb-225002,,,,,,,SB-225002,CXCR2,inhibitor of chemokine receptor 2,SB-225002
sb-431542,,,,,,,SB-431542,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptor,SB-431542
sb-525334,,,,,,,SB-525334,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptor,SB-525334
sb-743921,,,,,,,SB-743921,KIF11,inhibitor of kinesin 11,SB-743921
sb216763,,,SB216763,"SB-216763, SB 216763",GSK3A; GSK3B,WNT signaling,,,,SB-216763; SB 216763; SB216763
sb505124,,,SB505124,"SB 505124, SB505124",ALK4; ALK5,RTK signaling,,,,SB 505124; SB505124
sb52334,,,SB52334,"SB-52334, SB 52334",ALK5,RTK signaling,,,,SB 52334; SB-52334; SB52334
sb590885,,,SB590885,SB-590885,BRAF,ERK MAPK signaling,,,,SB590885; SB-590885
sch-529074,,,,,,,SCH-529074,TP53,activator of mutant p53,SCH-529074
sch-79797,,,,,,,SCH-79797,F2R,antagonist of proteinase-activated receptor 1 (PAR1),SCH-79797
seliciclib,,,Seliciclib,"Roscovitine, CYC-202, AL-39256",CDK2; CDK7; CDK9,Cell cycle,,,,CYC-202; Seliciclib; Roscovitine; AL-39256
selisistat,,,Selisistat,"EX-527, EX 527",SIRT1,Chromatin histone acetylation,EX-527,SIRT1,inhibitor of sirtuin 1,EX-527; Selisistat; EX 527
selumetinib,AZD6244,MEK,Selumetinib,"AZD6244, AZD-6244, ARRY-886",MEK1; MEK2,ERK MAPK signaling,selumetinib,MAP2K1; MAP2K2,inhibitor of MEK1 and MEK2,Selumetinib; ARRY-886; selumetinib; AZD-6244; AZD6244
selumetinib:brd-a02303741 (4:1 mol/mol),,,,,,,selumetinib:BRD-A02303741 (4:1 mol/mol),MAP2K1; MAP2K2; DOT1L,inhibitor of MEK1 and MEK2;inhibitor of histone methyltransferases,selumetinib:BRD-A02303741 (4:1 mol/mol)
selumetinib:decitabine (4:1 mol/mol),,,,,,,selumetinib:decitabine (4:1 mol/mol),MAP2K1; MAP2K2; DNMT1,inhibitor of MEK1 and MEK2;inhibitor of DNA methyltransferase,selumetinib:decitabine (4:1 mol/mol)
selumetinib:gdc-0941 (4:1 mol/mol),,,,,,,selumetinib:GDC-0941 (4:1 mol/mol),MAP2K1; MAP2K2; PIK3CA; PIK3CB; PIK3CD; PIK3CG,inhibitor of MEK1 and MEK2;inhibitor of PI3K kinase activity,selumetinib:GDC-0941 (4:1 mol/mol)
selumetinib:jq-1 (4:1 mol/mol),,,,,,,selumetinib:JQ-1 (4:1 mol/mol),MAP2K1; MAP2K2; BRDT,inhibitor of MEK1 and MEK2;inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,selumetinib:JQ-1 (4:1 mol/mol)
selumetinib:mk-2206 (8:1 mol/mol),,,,,,,selumetinib:MK-2206 (8:1 mol/mol),MAP2K1; MAP2K2; AKT1,inhibitor of MEK1 and MEK2;inhibitor of AKT1,selumetinib:MK-2206 (8:1 mol/mol)
selumetinib:navitoclax (8:1 mol/mol),,,,,,,selumetinib:navitoclax (8:1 mol/mol),MAP2K1; MAP2K2; BCL2; BCL2L1; BCL2L2,"inhibitor of MEK1 and MEK2;inhibitor of BCL2, BCL-xL, and BCL-W",selumetinib:navitoclax (8:1 mol/mol)
selumetinib:piperlongumine (8:1 mol/mol),,,,,,,selumetinib:piperlongumine (8:1 mol/mol),MAP2K1; MAP2K2,inhibitor of MEK1 and MEK2;natural product; modulator of ROS levels,selumetinib:piperlongumine (8:1 mol/mol)
selumetinib:plx-4032 (8:1 mol/mol),,,,,,,selumetinib:PLX-4032 (8:1 mol/mol),MAP2K1; MAP2K2; BRAF,inhibitor of MEK1 and MEK2;inhibitor of BRAF,selumetinib:PLX-4032 (8:1 mol/mol)
selumetinib:tretinoin (2:1 mol/mol),,,,,,,selumetinib:tretinoin (2:1 mol/mol),MAP2K1; MAP2K2; RARA; RARB; RARG,inhibitor of MEK1 and MEK2;agonist of retinoid acid receptors,selumetinib:tretinoin (2:1 mol/mol)
selumetinib:unc0638 (4:1 mol/mol),,,,,,,selumetinib:UNC0638 (4:1 mol/mol),MAP2K1; MAP2K2; EHMT1; EHMT2,inhibitor of MEK1 and MEK2;inhibitor of EHMT2 and GLP methyltransferase,selumetinib:UNC0638 (4:1 mol/mol)
selumetinib:vorinostat (8:1 mol/mol),,,,,,,selumetinib:vorinostat (8:1 mol/mol),MAP2K1; MAP2K2; HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of MEK1 and MEK2;inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",selumetinib:vorinostat (8:1 mol/mol)
semagacestat,,,,,,,semagacestat,APH1A; NCSTN; PSEN1; PSENEN,inhibitor of gamma-secretase,semagacestat
sepantronium bromide,,,Sepantronium bromide,"YM155, YM-155, YM 155",BIRC5,Apoptosis regulation,YM-155,BIRC5,inhibitor of survivin expression,Sepantronium bromide; YM 155; YM155; YM-155
serdemetan,,,Serdemetan,JNJ-26854165,MDM2,p53 pathway,serdemetan,MDM2,inhibitor of MDM2,JNJ-26854165; Serdemetan; serdemetan
serdemetan:sch-529074 (1:1 mol/mol),,,,,,,serdemetan:SCH-529074 (1:1 mol/mol),MDM2; TP53,inhibitor of MDM2;activator of mutant p53,serdemetan:SCH-529074 (1:1 mol/mol)
sgc0946,,,SGC0946,,DOT1L,Chromatin histone methylation,,,,SGC0946
sgx-523,,,,,,,SGX-523,MET,inhibitor of MET,SGX-523
shikonin,,,Shikonin,Anchusin,not defined,Other,,,,Anchusin; Shikonin
sid 26681509,,,,,,,SID 26681509,CTSL1,inhibitor of cathepsin L,SID 26681509
sildenafil,,,,,,,sildenafil,PDE5A,inhibitor of phosphodiesterase 5A,sildenafil
silmitasertib,,,,,,,silmitasertib,CSNK2A1; CSNK2A2,inhibitor of casein kinase 2,silmitasertib
simvastatin,,,,,,,simvastatin,HMGCR,inhibitor of HMG-CoA reductase,simvastatin
sirolimus,,,Rapamycin,"AY-22989, Sirolimus, WY-090217, Torisel, Rapamune",MTORC1,PI3K/MTOR signaling,sirolimus,MTOR,inhibitor of mTOR,WY-090217; AY-22989; Sirolimus; Torisel; Rapamycin; Rapamune; sirolimus
sirolimus:bortezomib (250:1 mol/mol),,,,,,,sirolimus:bortezomib (250:1 mol/mol),MTOR; PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of mTOR;inhibitor of 26S proteasome,sirolimus:bortezomib (250:1 mol/mol)
sitagliptin,,,,,,,sitagliptin,DPP4,inhibitor of dipetidyl peptidase-4,sitagliptin
sj-172550,,,,,,,SJ-172550,MDM2; TP53,inhibitor of p53-MDM2 interaction,SJ-172550
skepinone-l,,,,,,,skepinone-L,MAPK14,inhibitor of p38 MAPK,skepinone-L
ski-ii,,,,,,,SKI-II,SPHK1,inhibitor of sphingosine kinase 1,SKI-II
sl0101,,,SL0101,"SL-0101, SL 0101-1",RSK; AURKB; PIM1; PIM3,Other,,,,SL0101; SL 0101-1; SL-0101
smer-3,,,,,,,SMER-3,CUL1; SKP1,inhibitor of E3-ubiquitin ligase,SMER-3
sn-38,,,SN-38,"7-Ethyl-10-Hydroxy-Camptothecin, SN 38",TOP1,DNA replication,SN-38,TOP1,metabolite of irinotecan; inhibitor of topoisomerase I,7-Ethyl-10-Hydroxy-Camptothecin; SN 38; SN-38
sns-032,,,,,,,SNS-032,CDK16; CDK17; CDK2; CDK7; CDK9; CDKL5,inhibitor of cyclin-dependent kinases,SNS-032
snx-2112,,,SNX-2112,SNX 2112,HSP90,Protein stability and degradation,SNX-2112,HSP90AA1; HSP90B1,inhibitor of HSP90alpha and HSP90beta,SNX 2112; SNX-2112
snx-2112:bortezomib (250:1 mol/mol),,,,,,,SNX-2112:bortezomib (250:1 mol/mol),HSP90AA1; HSP90B1; PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of HSP90alpha and HSP90beta;inhibitor of 26S proteasome,SNX-2112:bortezomib (250:1 mol/mol)
sorafenib,Sorafenib,RTK,Sorafenib,"Nexavar, 284461-73-0, BAY 43-9006",PDGFR; KIT; VEGFR; RAF,RTK signaling,sorafenib,BRAF; FLT3; KDR; RAF1,"inhibitor of BRAF, CRAF, and VEGFR2",sorafenib; Nexavar; Sorafenib; 284461-73-0; BAY 43-9006
sotrastaurin,,,,,,,sotrastaurin,PRKCB,inhibitor of protein kinase C beta,sotrastaurin
spautin-1,,,,,,,spautin-1,USP10; USP13,inhibitor of the deubiquitinase activity of USP13 and USP10,spautin-1
sr-ii-138a,,,,,,,SR-II-138A,EIF4A2; EIF4E; EIF4G1,silvestrol analog; inhibits translation by modulating the eIF4F complex,SR-II-138A
sr1001,,,,,,,SR1001,RORA; RORC,synthetic ROR ligand; suppressor of TH17 differentiation,SR1001
sr8278,,,,,,,SR8278,NR1D1,antagonist of Rev-ErbAalpha,SR8278
srt-1720,,,,,,,SRT-1720,SIRT1,activator of sirtuin-1,SRT-1720
staurosporine,,,,,,,staurosporine,,inhibitor of multiple kinases,staurosporine
stemregenin 1,,,,,,,StemRegenin 1,AHR,inhibitor of aryl hydrocarbon receptor,StemRegenin 1
stf-31,,,,,,,STF-31,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,STF-31
stf-62247,,,STF-62247,STF62247,Autophagy inducer,Other,,,,STF-62247; STF62247
su11274,,,,,,,SU11274,MET,inhibitor of MET,SU11274
sunitinib,,,Sunitinib,"Sutent, Sunitinib Malate, SU-11248",PDGFR; KIT; VEGFR; FLT3; RET; CSF1R,RTK signaling,sunitinib,FLT1; FLT3; KDR; KIT; PDGFRA; PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta",Sunitinib; Sunitinib Malate; Sutent; sunitinib; SU-11248
sz4ta2,,,,,,,SZ4TA2,BCL2L1,inhibitor of BCL-xL,SZ4TA2
t0901317,,,T0901317,"TO-901317, TO901317",LXR; FXR,Other,,,,T0901317; TO-901317; TO901317
tacedinaline,,,,,,,tacedinaline,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",tacedinaline
tacrolimus,,,,,,,tacrolimus,PPP3CA; PPP3CB; PPP3CC; PPP3R1; PPP3R2,inhibitor of calcineurin,tacrolimus
tae684,TAE684,ALK,NVP-TAE684,"NVP-TAE 684, TAE684, TAE-684",ALK,RTK signaling,NVP-TAE684,ALK,inhibitor of ALK and ALK-NPM fusion protein,TAE684; NVP-TAE684; NVP-TAE 684; TAE-684
tak-715,,,TAK-715,"KIN001-201, TAK 715",p38alpha; p38beta,JNK and p38 signaling,,,,KIN001-201; TAK 715; TAK-715
talazoparib,,,Talazoparib,"BMN-673, BMN 973",PARP1; PARP2,Genome integrity,,,,BMN-673; BMN 973; Talazoparib
tamatinib,,,,,,,tamatinib,SYK,inhibitor of spleen tyrosine kinase,tamatinib
tamoxifen,,,Tamoxifen,"Nolvadex, Soltamox, Zynoplex, ICI-46474, Kessar",ESR1,Hormone-related,tamoxifen,ESR1; ESR2,modulator of estrogen receptors,Soltamox; ICI-46474; tamoxifen; Tamoxifen; Kessar; Nolvadex; Zynoplex
tandutinib,,,,,,,tandutinib,FLT3; KIT,inhibitor of c-KIT and VEGFR3,tandutinib
tanespimycin,17-AAG,HSP90,Tanespimycin,"17-AAG, BMS-722782",HSP90,Protein stability and degradation,tanespimycin,HSP90AA1,inhibitor of HSP90,tanespimycin; Tanespimycin; BMS-722782; 17-AAG
tanespimycin:bortezomib (250:1 mol/mol),,,,,,,tanespimycin:bortezomib (250:1 mol/mol),HSP90AA1; PSMB1; PSMB2; PSMB5; PSMD1; PSMD2,inhibitor of HSP90;inhibitor of 26S proteasome,tanespimycin:bortezomib (250:1 mol/mol)
tanespimycin:gemcitabine (1:1 mol/mol),,,,,,,tanespimycin:gemcitabine (1:1 mol/mol),HSP90AA1; CMPK1; RRM1; TYMS,"inhibitor of HSP90;inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase ",tanespimycin:gemcitabine (1:1 mol/mol)
temozolomide,,,Temozolomide,"Temodar, Temodal, M-39831, SCH 52365",DNA alkylating agent,DNA replication,temozolomide,,DNA alkylator,temozolomide; M-39831; Temodar; Temodal; SCH 52365; Temozolomide
temsirolimus,,,Temsirolimus,"CCI-779, Torisel",MTOR,PI3K/MTOR signaling,temsirolimus,MTOR,inhibitor of mTOR,Temsirolimus; temsirolimus; CCI-779; Torisel
teniposide,,,,,,,teniposide,TOP2A; TOP2B,inhibitor of topoisomerase II,teniposide
tg-100-115,,,,,,,TG-100-115,PIK3CD; PIK3CG,inhibitor of PI3K catalytic subunits delta and gamma,TG-100-115
tgx221,,,TGX221,"TGX-221, Tgx 221",PI3Kbeta,PI3K/MTOR signaling,TGX-221,PIK3CB,inhibitor of PI3K catalytic subunit beta,TGX-221; Tgx 221; TGX221
thalidomide,,,,,,,thalidomide,CRBN,immunomodulatory drug; binder of cereblon,thalidomide
thapsigargin,,,Thapsigargin,Octanoic acid,SERCA,Other,,,,Octanoic acid; Thapsigargin
thz-2-102-1,,,THZ-2-102-1,,CDK7,Cell cycle,,,,THZ-2-102-1
thz-2-49,,,THZ-2-49,,CDK9,Cell cycle,,,,THZ-2-49
tigecycline,,,,,,,tigecycline,,analog of tetracycline,tigecycline
tipifarnib,,,Tipifarnib,Zarnestra,Farnesyl-transferase (FNTA),Other,,,,Tipifarnib; Zarnestra
tipifarnib-p1,,,,,,,tipifarnib-P1,FNTA,inhibitor of farnesyltransferase,tipifarnib-P1
tipifarnib-p2,,,,,,,tipifarnib-P2,FNTA,inhibitor of farnesyltransferase,tipifarnib-P2
tivantinib,,,,,,,tivantinib,MET,inhibitor of MET; inhibitor of microtubule assembly,tivantinib
tivozanib,,,Tivozanib,"AV-951, AV 951, KRN-951, KIL8951, ASP-4130",VEGFR1; VEGFR2; VEGFR3,RTK signaling,tivozanib,FLT1; FLT3; KDR,inhibitor of VEGFRs,AV-951; KIL8951; AV 951; KRN-951; ASP-4130; Tivozanib; tivozanib
tki258,TKI258,FGFR,,,,,,,,TKI258
tl-1-85,,,TL-1-85,,TAK,"Other, kinases",,,,TL-1-85
tl-2-105,,,TL-2-105,,not defined,Unclassified,,,,TL-2-105
topotecan,Topotecan,TOP1,,,,,topotecan,TOP1,inhibitor of topoisomerase I,topotecan; Topotecan
tosedostat,,,,,,,tosedostat,ANPEP; LAP3; NPEPPS,"inhibitor of leucine aminopeptidase 3 (LAP), puromycin-sensitive aminopeptidase (PuSA), and aminopeptidase N",tosedostat
tozasertib,,,Tozasertib,"MK 0457,MK-0457,MK-045, VX-680 VX 680 VX-68",AURKA; AURKB; AURKC; others,Mitosis,,,,"MK 0457,MK-0457,MK-045; VX-680 VX 680 VX-68; Tozasertib"
tpca-1,,,TPCA-1,,IKK2,"Other, kinases",TPCA-1,IKBKB,inhibitor of IKK-2,TPCA-1
trametinib,,,Trametinib,"GSK1120212, Mekinist",MEK1; MEK2,ERK MAPK signaling,trametinib,MAP2K1; MAP2K2,inhibitor of MEK1 and MEK2,Mekinist; Trametinib; trametinib; GSK1120212
tretinoin,,,Tretinoin,"ATRA, Vesanoid, Renova, Atralin, Tretin-X, Avita",Retinoic acid ,Other,tretinoin,RARA; RARB; RARG,agonist of retinoid acid receptors,Avita; ATRA; Tretinoin; Tretin-X; Atralin; tretinoin; Renova; Vesanoid
tretinoin:carboplatin (2:1 mol/mol),,,,,,,tretinoin:carboplatin (2:1 mol/mol),RARA; RARB; RARG,agonist of retinoid acid receptors;inducer of DNA damage,tretinoin:carboplatin (2:1 mol/mol)
tretinoin:navitoclax (4:1 mol/mol),,,,,,,tretinoin:navitoclax (4:1 mol/mol),RARA; RARB; RARG; BCL2; BCL2L1; BCL2L2,"agonist of retinoid acid receptors;inhibitor of BCL2, BCL-xL, and BCL-W",tretinoin:navitoclax (4:1 mol/mol)
triazolothiadiazine,,,,,,,triazolothiadiazine,PDE4A; PDE4B; PDE4D,inhibitor of phosphdiesterase 4A/B/D,triazolothiadiazine
trifluoperazine,,,,,,,trifluoperazine,DRD2,antagonist of dopamine receptor D2,trifluoperazine
triptolide,,,,,,,triptolide,,natural product; inhibitor of RNA polymerase II,triptolide
tubastatin a,,,Tubastatin A,,HDAC1; HDAC6; HDAC8,Chromatin histone acetylation,tubastatin A,HDAC6,inhibitor of tubulin deacetylase activity of HDAC6,tubastatin A; Tubastatin A
tw-37,,,TW 37,"TW37, TW-37",BCL2; BCL-XL; MCL1,Apoptosis regulation,TW-37,BCL2; BCL2L1,inhibitor of BCL2 and BCL-xL,TW37; TW-37; TW 37
unc0321,,,,,,,UNC0321,EHMT2,inhibitor of G9a histone methyltransferase,UNC0321
unc0638,,,UNC0638,"UNC-0638, UNC 0683",G9a and GLP methyltransferases,Chromatin histone methylation,UNC0638,EHMT1; EHMT2,inhibitor of EHMT2 and GLP methyltransferase,UNC-0638; UNC0638; UNC 0683
unc0638:navitoclax (1:1 mol/mol),,,,,,,UNC0638:navitoclax (1:1 mol/mol),EHMT1; EHMT2; BCL2; BCL2L1; BCL2L2,"inhibitor of EHMT2 and GLP methyltransferase;inhibitor of BCL2, BCL-xL, and BCL-W",UNC0638:navitoclax (1:1 mol/mol)
unc1215,,,UNC1215,UNC-1215,L3MBTL3,Chromatin other,,,,UNC-1215; UNC1215
vaf-347,,,,,,,VAF-347,AHR,inhibitor of aryl hydrocarbon receptor,VAF-347
valdecoxib,,,,,,,valdecoxib,PTGS2,inhibitor of cyclooxygenase-2 (COX2),valdecoxib
vandetanib,,,,,,,vandetanib,EGFR; KDR,inhibitor of VEGFR2 and EGFR,vandetanib
veliparib,,,Veliparib,"ABT-888, ABT888, ABT 888",PARP1; PARP2,Genome integrity,veliparib,PARP1; PARP2,inhibitor of poly (ADP-ribose) polymerase 1 (PARP1) and 2 (PARP2),ABT 888; Veliparib; veliparib; ABT888; ABT-888
ver-155008,,,,,,,VER-155008,HSPA1A; HSPA1B; HSPA1L,inhibitor of HSP70,VER-155008
vinblastine,,,Vinblastine,Velban,Microtubule destabiliser,Mitosis,,,,Vinblastine; Velban
vincristine,,,,,,,vincristine,,inhibitor of mictrotubule assembly,vincristine
vinorelbine ,,,Vinorelbine ,"vinorelbine tartrate, Navelbine, Exelbine",Microtubule destabiliser,Mitosis,,,,Navelbine; Exelbine; Vinorelbine ; vinorelbine tartrate
vismodegib,,,Vismodegib,"GDC0449, Erivedge",SMO,Other,,,,Vismodegib; Erivedge; GDC0449
vnlg/124,,,VNLG/124,HDAC inhibitor XV,"HDAC,RAR",Chromatin histone acetylation,,,,HDAC inhibitor XV; VNLG/124
vorapaxar,,,,,,,vorapaxar,F2R,antagonist of proteinase-activated receptor 1 (PAR1),vorapaxar
vorinostat,,,Vorinostat,"Zolinza, SAHA, suberanilohydroxamic acid, suberoylanilide hydroxamic acid, MK-0683",HDAC inhibitor Class I; IIa; IIb; IV,Chromatin histone acetylation,vorinostat,HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",suberoylanilide hydroxamic acid; vorinostat; suberanilohydroxamic acid; SAHA; MK-0683; Zolinza; Vorinostat
vorinostat:carboplatin (1:1 mol/mol),,,,,,,vorinostat:carboplatin (1:1 mol/mol),HDAC1; HDAC2; HDAC3; HDAC6; HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8;inducer of DNA damage",vorinostat:carboplatin (1:1 mol/mol)
vorinostat:navitoclax (4:1 mol/mol),,,,,,,vorinostat:navitoclax (4:1 mol/mol),HDAC1; HDAC2; HDAC3; HDAC6; HDAC8; BCL2; BCL2L1; BCL2L2,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8;inhibitor of BCL2, BCL-xL, and BCL-W",vorinostat:navitoclax (4:1 mol/mol)
vu0155056,,,,,,,VU0155056,PLD1; PLD2,inhibitor of phospholipase D1/D2,VU0155056
vx-11e,,,VX-11e,"VX11e, VX11e",ERK2,ERK MAPK signaling,,,,VX-11e; VX11e
vx-680,,,,,,,VX-680,AURKA; AURKB; AURKC,inhibitor of aurora kinases,VX-680
vx-702,,,VX-702,"VX702, VX 702",p38,JNK and p38 signaling,,,,VX702; VX-702; VX 702
way-362450,,,,,,,WAY-362450,NR1H4,agonist of farnesoid X receptor,WAY-362450
wee1 inhibitor,,,Wee1 Inhibitor,"681640, Wee1 Inhibitor",WEE1; CHEK1,Cell cycle,,,,681640; Wee1 Inhibitor
wh-4-023,,,WH-4-023,KIN001-112,SRC; LCK,"Other, kinases",,,,KIN001-112; WH-4-023
whi-p97,,,WHI-P97,"AC1L1GQE, KIN001-055",JAK3,"Other, kinases",,,,WHI-P97; KIN001-055; AC1L1GQE
wp1130,,,,,,,WP1130,UCHL5; USP14; USP5; USP9X,"inhibitor of the deubiquitinase activity of USP9X, USP5, USP14, and UCH37",WP1130
wz-1-84,,,WZ-1-84,KIN001-123,BMX,"Other, kinases",,,,WZ-1-84; KIN001-123
wz3105,,,WZ3105,,SRC; ROCK2; NTRK2; FLT3; IRAK1; others,Other,,,,WZ3105
wz4002,,,,,,,WZ4002,EGFR,inhibitor of EGFR targeting T790M resistance,WZ4002
wz8040,,,,,,,WZ8040,EGFR,inhibitor of EGFR targeting T790M resistance,WZ8040
xav939,,,XAV939,"NVP-XAV939, XAV-939, XAV 939",TNKS1; TNKS2,WNT signaling,,,,XAV939; XAV 939; XAV-939; NVP-XAV939
xl765,,,,,,,XL765,MTOR; PIK3CA; PIK3CB; PIK3CD; PIK3CG; PRKDC,inhibitor of mTOR and PI3K kinase acitivities,XL765
xmd11-85h,,,XMD11-85h,,BRSK2; FLT4; MARK4; PRKCD; RET; SPRK1,Other,,,,XMD11-85h
xmd13-2,,,XMD13-2,,RIPK1,Apoptosis regulation,,,,XMD13-2
xmd14-99,,,XMD14-99,,ALK; CDK7; LTK; others,Other,,,,XMD14-99
xmd15-27,,,XMD15-27,,CAMK2,"Other, kinases",,,,XMD15-27
xmd8-85,,,XMD8-85,ERK5-IN-1,ERK5; BET,Other,,,,XMD8-85; ERK5-IN-1
xmd8-92,,,XMD8-92,XMD 8-92,MAPK7,"Other, kinases",,,,XMD8-92; XMD 8-92
y-39983,,,Y-39983,,ROCK,Cytoskeleton,,,,Y-39983
yk-4-279,,,YK-4-279,YK 4-279,RNA helicase A,Other,YK 4-279,DHX9; ERG; ETV1,inhibitor of RNA helicase A (RHA) binding to EWS-FLI1; inhibitor of ERG and ETV1 activity,YK-4-279; YK 4-279
yl54,,,,,,,YL54,,stapled helical peptide,YL54
ym201636,,,YM201636,"YM-201636, YM 201636",PYKFYVE,Other,,,,YM201636; YM 201636; YM-201636
z-llnle-cho,,,Z-LLNle-CHO,"Z-L-Norleucine-CHO, Gamma-Secretase Inhibitor 1",gamma-secretase,Other,,,,Gamma-Secretase Inhibitor 1; Z-L-Norleucine-CHO; Z-LLNle-CHO
zd-6474,ZD-6474,EGFR,,,,,,,,ZD-6474
zebularine,,,,,,,zebularine,DNMT1,inhibitor of DNA methyltransferases,zebularine
zg-10,,,ZG-10,,JNK1,JNK and p38 signaling,,,,ZG-10
zibotentan,,,Zibotentan,"ZD4054, ZD-4054",Endothelin-1 receptor (EDNRA),Other,,,,Zibotentan; ZD4054; ZD-4054
zm447439,,,ZM447439,"ZM-447439, ZM 447439",AURKA; AURKB,Mitosis,,,,ZM447439; ZM 447439; ZM-447439
zstk474,,,ZSTK474,"KIN001-167, ZSTK-474, ZSTK 474",PI3K (class 1),PI3K/MTOR signaling,ZSTK474,PIK3CB; PIK3CD; PIK3CG,"inhibitor of PI3K catalytic subunits beta, delta, and gamma",ZSTK-474; ZSTK 474; ZSTK474; KIN001-167
